EP1551964A2 - Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms - Google Patents
Methods and compositions for extending the life span and increasing the stress resistance of cells and organismsInfo
- Publication number
- EP1551964A2 EP1551964A2 EP03788377A EP03788377A EP1551964A2 EP 1551964 A2 EP1551964 A2 EP 1551964A2 EP 03788377 A EP03788377 A EP 03788377A EP 03788377 A EP03788377 A EP 03788377A EP 1551964 A2 EP1551964 A2 EP 1551964A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cell
- nicotinamide
- cells
- sir2
- nad
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
Definitions
- yeast replicative aging has been shown to stem from the instability of the repeated ribosomal DNA (rDNA) locus (16). This instability gives rise to circular forms of rDNA called ERCs that replicate but fail to segregate to daughter cells.
- rDNA repeated ribosomal DNA
- ERCs accumulate to over 1000 copies, which are thought to kill cells by titrating essential transcription and/or replication factors. (16-18).
- Regimens that reduce DNA recombination such as caloric restriction or afobl deletion extend replicative life span (17,19,20).
- Sir2 silencing protein 17
- a nicotinamide adenine dinucleotide (NAD + )-dependent deacetylase 21-24
- Sir2 is a component of the heterotrimeric Sir2/3/4 complex that catalyzes the formation of silent heterochromatin at telomeres and the two silent mating-type loci (25).
- Sir2 is also a component of the RENT complex that is required for silencing at the rDNA locus and exit from telophase (26,27). This complex has also recently been shown to directly stimulate transcription of rRNA by Pol I and to be involved in regulation of nucleolar structure (28).
- NAD+ may be synthesized de novo from tryptophan or recycled in four steps from nicotinamide via the NAD+ salvage pathway.
- the first step in the bacterial NAD + salvage pathway the hydrolysis of nicotinamide to nicotinic acid and ammonia, is catalyzed by the pncA gene product (33).
- SGD S. cerevisiae gene with homology to pncA, YGL037
- NAD + salvage pathway and the de novo NAD + pathway converge and NaMN is converted to desamido-NAD +
- NAD nicotinate mononucleotide adenylyltransferase
- null mutations in NPTl reduce steady-state NAD + levels by ⁇ 2-fold (23) and abolish the longevity provided by limiting calories (19).
- One current hypothesis explaining how caloric restriction extends replicative life span is that decreased metabolic activity causes an increase in NAD + levels, which then stimulate Sir2 activity (reviewed in Campisi, 2000 and Guarente, 2000).
- Transcriptional silencing involves the heritable modification of chromatin at distinct sites in the genome. Silencing is referred to as long-range repression as it is promoter nonspecific and often encompasses an entire genomic locus (l',2'). In yeast these silent regions of DNA, which are similar to the heterochromatin of higher eukaryotes, are subject to a wide variety of modifications (3'). Among the most well studied of these modifications is the reversible acetylation of histones (reviewed in 4',5'). There are two classes of enzymes that affect the acetylation state of histones: histone acetyltransferases (HATs) and the opposing histone deacetylases (HDACs).
- HATs histone acetyltransferases
- HDACs opposing histone deacetylases
- histones within silent regions of chromatin are known to be hypoacetylated, specifically on the NH 2 -terminal tails of core histones H3 and H4 (6').
- Three classes of histone deacetylases have been described and classified based on homology to yeast proteins. Proteins in class I (Rpd3-like) and class II (Hdal-like) are characterized by their sensitivity to the inhibitor trichostatin A (TSA) (7',8'). Studies using this inhibitor have provided a wealth of information regarding the cellular function of these proteins, including their involvement in the expression of regulators of cell cycle, differentiation, and apoptosis (reviewed in 9').
- TSA trichostatin A
- Yeast Sir2 is the founding member of Class III HDACs. Sir2-like deacetylases are not inhibited by TSA and have the unique characteristic of being NAD + -dependent (10'- 13'). Proteins of this class are found in a wide array of organisms, ranging from bacteria to humans. At least two Sir2 homologues, yeast Hst2 and human SIRT2, are localized to the cytoplasm and human SIRT1 has recently been shown to target p53 for deacetylation (11',13'-15'). These results indicate that not all members of this family are specific for histones or other nuclear substrates.
- silent information regulator was first coined to describe a set of non-essential genes required for repression of the mating type loci (HML and HMR) in S. cerevisiae (16'). Silencing in yeast is also observed at telomeres and the ribosomal DNA (rDNA) locus (2', 17'). The formation of heterochromatin at mating type loci and the poly(TG ⁇ - ) tracts of yeast telomeres is mediated by a heterotrimeric complex of Sir2, Sir3 and Sir4 (18', 19').
- Sir2 is part of the RENT (regulator of wuleolar silencing and telophase exit) complex, which includes Netl and Cdcl4 (20',21'). Of these proteins, Sir2 is the only factor that is indispensable for silencing at all three silent regions (22'-24').
- the yeast rDNA locus (RDN1) consists of 100-200 tandemly-repeated 9 kb units encoding ribosomal RNAs.
- a major cause of yeast aging has been shown to stem from recombination between these repeats (25'-27') which can lead to the excision of an extrachromosomal rDNA circle (ERC).
- ERCs are replicated but they fail to segregate to daughter cells, resulting in their exponential amplification as cells divide. ERCs can accumulate to a DNA content greater than that of the entire yeast genome in old cells and are thought to kill cells by titrating essential transcription and/or replication factors (28').
- SIR2 is essential for the increased longevity provided by calorie restriction (31 "), a regimen that extends the life span of every organism it has been tested on.
- increased dosage of the Sir2 homologue sir2.1 has been shown to extend the life span of the nematode C. elegans (33') and the nearest human homologue SIRTl, has been shown to inhibit apoptosis through deacetylation of p53 (34',35').
- Sir2 Upon cleavage, Sir2 catalyzes the transfer of an acetyl group to ADP-ribose (10',11',15',37').
- ADP-ribose (10',11',15',37').
- the product of this transfer reaction is O- acetyl- ADP-ribose, a novel metabolite, which has recently been shown to cause a delay/block in the cell cycle and oocyte maturation of embryos (38').
- nicotinamide a precursor of nicotinic acid and a form of vitamin B3 (39').
- High doses of nicotinamide and nicotinic acid are often used interchangeably to self-treat a range of conditions including anxiety, osteoarthritis, psychosis, and nicotinamide is currently in clinical trials as a therapy for cancer and type I diabetes (40').
- the long-term safety of the high doses used in these treatments has been questioned (41 ') and the possible effects of these compounds at the molecular level are not clear. Summary of the invention
- the invention provides methods for modulating the life span of a cell or its resistance to stress, comprising modulating the flux through the NAD+ salvage pathway in the cell.
- the method may comprise increasing or extending the life of a cell or increasing its resistance against stress, comprising increasing the flux through the NAD+ salvage pathway in the cell.
- Modulating the flux through the NAD+ salvage pathway may occur essentially without changing steady state levels of NAD+ and NADH and essentially by maintaining the NAD+/NADH ratio in the cell.
- Increasing the flux throught the NAD+ salvage pathway may comprise increasing the level or activity of a protein selected from the group consisting of NPTl, PNC1, NMA1 and NMA2.
- the method may comprise introducing into the cell at least one nucleic acid encoding a protein selected from the group consisting of NPTl, PNC1, NMA1 and NMA2, or a nucleic acid comprising at least 5 copies of a gene.
- the method may comprise introducing into the cell at least one protein selected from the group consisting of NPTl, PNC1, NMA1 and NMA2.
- the method may comprise contacting the cell with an agent that upregulates the expression of a gene selected from the group consisting of NPTl, PNC1 , NMA1 and NMA2.
- the cell may live at least about 40% longer, or at least about 60% longer.
- the invention also provides methods for increasing the resistance of the cell against stress, e.g., heat shock, osmotic stress, DNA damaging agents (e.g., U.V.), and inadequate nitrogen levels, comprising increasing the flux through the NAD+ salvage pathway in the cell.
- stress e.g., heat shock, osmotic stress, DNA damaging agents (e.g., U.V.), and inadequate nitrogen levels
- modulating the life span of a cell comprises modulating silencing in the cell.
- Silencing may include telomeric silencing and rDNA recombination.
- the cell whose life span can be extended or who can be protected against stress can be a eukaryotic cell, such as a yeast cell or a prokaryotic cell, such as a bacterial cell.
- the cell can be in vitro or in vivo.
- modulating the life span of a cell or its resistance to stress comprises modulating the amount of nicotinamide in the cell.
- reducing the life span of a cell or rendering a cell more sensitive to stress may comprise increasing the level of nicotinamide in the cell. This may comprise contacting the cell with an amount of nicotinamide of about 1 to 20 mM, preferably of about 2 to 10 mM.
- the level of nicotinamide in a cell may also be increased by increasing the level or activity of enzymes involved in the biosynthesis of nicotinamide or by decreasing the level or activity of enzymes that degrade or inactivate nicotinamide.
- Enzymes which inactivate nicotinamide include PNCl; nicotinamide N-methyl transferase (NNMT and NNT1); nicotinamide phosphoribosyltransferase (NAMPRT); NPTl and human homologs thereof; and optionally nicotinamide mononucleotide adenylyltransferase (NMNAT- 1 and 2); NMAl and 2 and human homologs thereof.
- NMT and NNT1 nicotinamide N-methyl transferase
- NAMPRT nicotinamide phosphoribosyltransferase
- NMNAT- 1 and 2 optionally nicotinamide mononucleotide adenylyltransferase
- nicotinamide (i.e., less sensitive) to stress may comprise decreasing the level of nicotinamide in the cell. This may be achieved by decreasing the level or activity of enzymes involved in the biosynthesis of nicotinamide or by increasing the level or activity of enzymes that degrade or inactivate nicotinamide. Accordingly, increasing lifespan or stress resistance in a cell can be achieved by increasing the activity or level of expression of a protein selected from the group consisting of NPTl, PNCl, NMAl, NMA2, NNMT, NAMPRT, NMNAT- 1, and NMNAT-2.
- the invention further provides methods for identifying compounds that modulate the life span of a cell or its resistance to stress, comprising (i) contacting a protein selected from the group consisting of NPTl, PNCl, NMAl, NMA2, NNMT, NAMPRT, NMNAT- 1, and NMNAT-2 with a test compound for an amount of time that would be sufficient to affect the activity of the protein; and (ii) determining the activity of the enzyme, wherein a difference in the activity of the enzyme in the presence of the test compound relative to the absence of the test compound indicates that the test compound is a compound that modulates the life span of the cell or its resistance to stress.
- the method may further comprise contacting a cell with the test compound and determining whether the life span of the cell has been modulated.
- the method may also further comprise contacting a cell with the test compound and determining whether the resistance of the cell to stress has been modulated.
- the invention provides a method for identifying a compound that modulates the life span of a cell or its resistance to certain types of stresses, comprising (i) contacting a cell or a lysate, comprising a transcriptional regulatory nucleic acid of a gene selected from the group consisting of NPTl, PNCl, NMAl, NMA2, NNMT, NAMPRT, NMNAT- 1, and NMNAT-2 operably linked to a reporter gene, with a test compound for an amount of time that would be sufficient to affect the transcriptional regulatory nucleic acid; and (ii) determining the level or activity of the reporter gene, wherein a difference in the level or activity of the reporter gene in the presence of the test compound relative to the absence of the test compound indicates that the test compound is a compound that modulates the life span of the cell or its resistance to certain types of stresses.
- the method may further comprise contacting a cell with the test compound and determining whether the life span of the cell has been modulated.
- the method may also further comprise contacting a cell
- the method may comprise (i) providing a cell or cell lysate comprising a reporter construct that is sensitive to the level of nicotinamide in a cell; (ii) contacting the cell with a test agent; and (iii) determining the level of nicotinamide in the cell contacted with the test agent, wherein a different level of nicotinamide in the cell treated with the test agent relative to a cell not treated with the test agent indicates that the test agent modulates the level of nicotinamide in the cell.
- the cell may further comprise a vector encoding a fusion protein that can bind to a DNA binding element operably linked to the reporter gene.
- the fusion protein may comprise at least an NAD+ binding pocket of a nicotinamide sensitive enzyme, e.g., a Sir2 family member, and a heterologous polypeptide.
- the heterologous polypeptide may be a transactivation domain of a transcription factor.
- the method may further comprise contacting a cell with the test compound and determining whether the life span of the cell or its resistance to stress has been modulated.
- Also within the scope of the invention are computer-assisted methods for identifying an inhibitor of the activity of a Sir2 family member comprising: (i) supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex including at least a portion of a Sir2 family member comprising a C pocket; (ii) supplying the computer modeling application with a set of structure coordinates of a chemical entity; and (iii) determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of the activity of the Sir2 family member.
- the chemical entity may be an analog of nicotinamide.
- Another method for identifying an inhibitor of the activity of a Sir2 family member comprises: (i) contacting a protein of the Sir2 family comprising at least the C pocket with a test compound for a time sufficient for the test compound to potentially bind to the C pocket of the protein of the Sir2 family; and (ii) determining the activity of protein; wherein a lower activity of the protein in the presence of the test compound relative to the absence of the test compound indicates that the test compound is an inhibitor of the activity of a Sir2 family member.
- the invention provides methods for treating or preventing diseases that are associated with cell death (e.g., apoptosis) in a subject, comprising administering to a subject in need thereof an agent that increases the flux through the NAD+ salvage pathway or reduces nicotinamide levels in the cells susceptible or subject to cell death.
- Diseases can be chronic or acute and include Alzheimer's disease, Parkinson's disease, stroke and myocardial infarction.
- the methods of the invention for extending life span or increasing resistance to stress can also be used to reduce aging, e.g., for cosmetic purposes.
- the agent can be administered locally or systemically. Methods for extending life span or increasing resistance to stress can also be used on cells, tissues or organs outside of a subject, e.g., in an organ or tissue prior to transplantation.
- the invention also provides methods for treating or preventing diseases in which reducing the life span of cells or rendering cell sensitive to stress is beneficial.
- diseases include those in which cells are undesirable, e.g., cancer and autoimmune diseases.
- the methods of the invention can also be used to modulate the lifespan and stress resistance of organisms other than mammals.
- the method can be used in microorganisms and plants.
- the methods of the invention permit to increase the resistance of plants to high salt, drought or disease, e.g., by treating these with a chemical that lowers nicotinamide levels or by genetically modifying genes that modulate the NAD+ salvage pathway or the level of nicotinamide in cells.
- FIG. 1 Increased dosage of NPTl delays aging by mimicking caloric restriction. Life span was determined by scoring the number of daughter cells produced by each mother cell before cessation of cell division (7,10). Cells were pre-grown for a minimum of 48 h on complete glucose medium. A, Mortality curves for wild type (PSY316AT, circles), 2xNPTl (YDS1544, diamonds) and 5xNPTl (YDS 1548, triangles) on medium with 2% glucose. Average life spans are 21.9, 30.8 and 35.1 generations respectively.
- FIG. 2 Mortality curves for wild type on 2% glucose (PSY316AT, circles) and 0.5% glucose medium (PSY316AT, squares) and for 2xNR77 on 0.5% glucose medium (YDS1544, triangles). Average life spans are 21.9, 31.7 and 34.5 generations respectively.
- FIG. 2. NPTl and SIR2 provide resistance to heat shock.
- A Strains were grown for three days post-diauxic shift in SC medium and incubated for 1 h at 55°C before plating 10-fold dilutions on SC plates.
- .B Strains were treated as in A and plated on SC at low density. Colonies that aroze after 24 hours were scored and expressed as a percentage of colonies arizing from the untreated sample.
- FIG. 3 Additional NPTl increases silencing and rD ⁇ A stability.
- A Strains with an ADE2 marker at the rD ⁇ A were pre-grown on SC plates and spotted as 10-fold serial dilutions on SC plates. Increased silencing is indicated by growth retardation on media lacking adenine.
- FIG. 4 Expression of NPTl in response to caloric restriction and stress.
- A, 3xHA tag sequence was inserted in frame with the 3' end of the native NPTl ORF in W303AR5 (YDS 1531) and W303cdc 10-25 (YDS 1537). Cells were grown in YPD medium at 30°C and treated as described. Levels of NPTl mR ⁇ A were examined for W303AR5 grown in YPD (0.5% and 2.0% glucose) and ⁇ 303cdc25-10 grown in YPD (2% glucose). A 1.8 kb NPTl transcript was detected and levels were normalized to actin (ACT!) control. Similar results were obtained in the PSY316 strain background (not shown).
- GFP green fluorescent protein
- FIG. 5 Multiple limiting components in the NAD + salvage pathway.
- A The putative steps in NAD biosynthesis in S. cerevisiae based on the known steps in Salmonella. The yeast genes that are thought to mediate each step are shown in italics. NaMN, nicotinic acid mononucleotide; NaAD, desamido-NAD + ; NaM, nicotinamide; Na, nicotinic acid. Adapted from Smith et al. (2000).
- B Silencing of ADE2 at the rDNA locus in strains ADE2 (YDS 1596), wild type (W303AR5), 2xNPTl (YDS 1503), 2xPNCl (YDS1588), 2xNMA2 (YDS1589), 2xNMAl (YDS1590), and 2xQNSl (YDS1614). Increased silencing is indicated by growth retardation on media lacking adenine.
- C Strains with an ADE2 marker at the telomere were streaked onto SC medium containing limiting amounts of adenine. Silencing is indicated by the accumulation of a red pigment.
- FIG. 6 Model for life span extension via increased flux through the ⁇ AD + salvage pathway.
- Type III histone deacetylases such as Sir2 and Hstl-4 catalyze a key step in the salvage pathway by converting NAD + to nicotinamide. Additional copies of PNCl, NPTl, NMAl and NMA2 increase flux through the NAD + salvage pathway, which stimulates Sir2 activity and increases life span.
- NAD + nicotinamide adenine dinucleotide
- NaMN nicotinic acid mononucleotide
- NaAD desamido-NAD + .
- FIG. 7 The NAD + salvage pathway. Nicotinamide generated by Sir2 is converted into nicotinic acid by Pncl and subsequently back to NAD + in three steps. Abbreviations: NAD + , nicotinamide adenine dinucleotide; NaMN, nicotinic acid mononucleotide; NaAD, desamido-NAD + .
- Silencing of the MET 15 marker is indicated by the accumulation of a brown pigment.
- Single dark brown colonies in RDN1::MET15 strains represent marker loss events.
- Relevant genotypes met75--1 (JS209), MET15 (JS241), RDN1::MET15 (JS237), sir2::TRPl (JS218), 2xSIR2 (YDS 1583).
- B Strains with an ADE2 marker at the telomere were streaked onto SC medium containing limiting amounts of adenine and either 0 or 5 mM nicotinamide. Silencing of the ADE2 marker results in the accumulation of a red pigment.
- FIG.9 Nicotinamide increases rDNA recombination and shortens yeast life span.
- A Strains were assayed for rDNA stability by examining the rate of loss of an ADE2 marker integrated at the rDNA locus. Cells were plated on 2% glucose YPD medium with or without 5 mM nicotinamide (NAM) and the frequency of half-sectored colonies, reflecting a marker loss event at the first cell division, was measured. More than 10,000 colonies were examined for each strain and each experiment was performed in triplicate.
- NAM nicotinamide
- C Mortality curves for wild type (PSY316AT) and sir2::TRPl (YDS1594) strains in 0 or 5 mM nicotinamide (NAM). Average life spans were wt: 22.4, 12.1 and sir2: 12.1, 11.7 respectively.
- D Mortality curves for wild type and sir2 strains from C, in the presence of either 0, 5 mM or 50 mM nicotinic acid (NA). Average life spans were wt: 22.4, 26, 25 and -?/r2: 12.1, 12.2.
- FIG.10 Nicotinamide derepresses the silent mating type locus (HMR) in the both cycling and Gl arrested cells.
- A PSY316 cells containing an ADH driven GFP transcript inserted at the HMR locus (YDS970) were grown in YPD medium at 30°C to mid-log phase and treated with 5 mM nicotinamide (NAM) for the indicated times. Cells were photographed live.
- B Strain YDS970 or the isogenic sir4 ⁇ mutant (YDS 1499) were treated with either 5 mM nicotinamide (NAM), 5 mM nicotinic acid (NA) or 5 mM quinolinic acid (QA).
- FACS fluorescent activated cell sorting
- FIG.12. Sir2 does not associate with DNA from telomeres or mating type loci in the presence of nicotinamide.
- a andB Chromatin immunoprecipitation using a polyclonal ⁇ - Sir2 antibody was performed on extracts from either a sir2 (YDS878) (A) or wild type (W303AR5) (B) strains in the presence of 5 mM nicotinamide (NAM). PCR amplification of both input DNA from whole cell extracts and immunoprecipitated chromatin are shown.
- PCR was performed using primer pairs specific for the CUP1 gene (top panels), 5S rDNA (second panels), the HMR locus (third panels), or subtelomeric DNA 1.4 and 0.6 kb from telomeres (bottom panels). Primer sequences are listed in Table 4.
- FIG.13 Nicotinamide is a potent non-competitive inhibitor of yeast Sir2 and human SIRTl in vitro.
- A Recombinant GST-tagged Sir2 was incubated with acetylated substrate for 30 minutes at 30°C in the presence of 1 mM DTT, 200, 350, 500 or 750 ⁇ M NAD + and the indicated concentrations of nicotinamide. Reactions were terminated by the addition of developer and samples were analyzed by fluorometry (excitation set at 360 nm and emission at 460 nm). Experiments were performed in triplicate. Data is shown as a Lineweaver-Burk double reciprocal plot of arbitrary fluorescence units (AFUs) min " versus NAD + ( ⁇ M).
- AFUs arbitrary fluorescence units
- the left panel shows a frontal view of the surface representation of Sir2-Af 1 , with bound NAD + in purple and a red arrow pointing at the acetyl-lysine binding tunnel.
- the C site is traced with a dashed teal curve.
- the right panel shows the protein cut through the dashed line and rotated 90 degrees along its vertical axis.
- the surface of the conserved residues in the C site is colored teal.
- B Close-up view of the black rectangle drawn on the right panel of A, showing the nicotinamide docked deeply inside the C pocket of Sir2-Af 1.
- C Stereo view of the docked nicotinamide (green) surrounded by the conserved residues in the C pocket. The putative interactions are shown as dashed lines, including H-bonds (blue), electrostatic (magenta) and Van der Waals (yellow).
- Fig. 15 shows an alignment of NPTl homologs.
- Fig. 16 shows an alignment of PNCl homologs.
- Fig. 17 A-E. Calorie restriction and heat stress extend lifespan in a PNCl -dependent manner.
- A Pncl catalyses the conversion of nicotinamide to nicotinic acid.
- B In yeast NAD + is synthesised de novo from tryptophan and recycled from nicotinamide via the NAD + salvage pathway.
- C Lifespan extension by glucose restriction requires PNCl. Average lifespan on complete media containing 2.0% (w/v) glucose were: wild-type, (2 ⁇ .6);pncl ⁇ , (19.1); sir2 ⁇ , (14.2).
- FIG. 18A-D Pncl levels and activity are elevated in response to calorie restriction and stress.
- A Detection of Pncl -GFP in yeast whole cell extracts using an anti-GFP antibody. Actin levels are included as a loading control. Extracts were made from mid-log phase wild-type cultures grown in complete media with 2.0%, 0.5% or 0.1 % glucose (w/v).
- B Pncl -GFP levels in extracts from mid-log phase wild-type, cdc25-10 or bna ⁇ cultures detected as above.
- C Detection of Pncl -GFP in extracts from mid-log phase wild-type cultures as described above.
- PNCl confers resistance to acute stress.
- A Additional PNCl confers resistance to salt stress. Cells from mid-log phase colonies were struck out on complete medium containing 600 mM NaCl or 200 mM LiCl and incubated for 4 d at 25°C. On standard yeast medium (2% glucose, 25°C), there was no detectable difference in growth rate between wild-type, SxPNCl, or 5xPNCl sir2 ⁇ strains.
- B Additional PNCl protects against UV induced damage in a SIR2 independent manner. Cells from mid-log phase cultures were plated at low density on complete medium and exposed to UV (5 mJ/cm 2 , 254nm).
- Viability was determined by the ability to form colonies after 3 d growth in the dark at 30°C. Values are expressed as percent viable ⁇ s.e.
- C PNCl provides SIR2- independent protection against mitochondrial DNA damage. Microcolony analysis of log- phase cells streaked on complete 3% (v/v) glycerol medium and 10 ⁇ g/ml ethidium bromide (EtBr). At least 100 microcolonies were scored after 3 d in two independent experiments. Number of cells per colony ⁇ s.e. were: wild-type 6.92 ⁇ 0.06, SxPNCl 18.72 ⁇ 0.53, and SxPNCl sir2 ⁇ 16.15 ⁇ 2.82. No difference in growth was detected between these strains on complete 2% (w/v) glucose medium with EtBr
- Fig. 20A-D Pncl -GFP is localized in the cytoplasm and nucleus and is concentrated in peroxisomes.
- A Pncl -GFP fluorescence was detected in cells taken from mid-log phase wild-type cultures grown in complete media containing 2.0% glucose (unrestricted), or 0.5%) or 0.1% glucose (Glu).
- B Detection of Pncl-GFP in cells from wild-type cultures grown under the following conditions: amino acid (a.a) restriction (SD lacking non-essential amino acids), salt stress (300 mM NaCl), heat stress (37°C).
- C Co- localisation of Pncl-GFP (green) and RFP-PTS1 (Peroxisomal Targeting Signal 1) (red) in cells from mid-log phase wild-type cultures. Yellow indicates overlap. Cultures were grown in complete media containing 0.5%> glucose to facilitate visualization of fluorescence.
- D Localisation of Pncl-GFP in cells from mid-log phase cultures of peroxisomal mutant strains, pex ⁇ , pexS ⁇ and pex7 ⁇ . Cultures were grown in complete media containing 0.5% glucose to enhance visualization of fluorescence. All images were taken with the same exposure of 1 s.
- Fig. 21 A-B Manipulation of nicotinamide metabolism affects SIR2 dependent silencing
- A To measure silencing, an ADE2 reporter was integrated at the ribosomal DNA (rDNA) locus. In this system, increased growth on media lacking adenine indicates decreased ADE2 silencing. Strains were spotted in 10-fold serial dilutions on plates with or without adenine. An Ade + strain served as a control.
- Cells coordinate a response to these inputs by inducing transcription of PNCl, which encodes an enzyme that converts nicotinamide to nicotinic acid.
- PNCl which encodes an enzyme that converts nicotinamide to nicotinic acid.
- depletion of nicotinamide activates a number of additional target proteins involved in stress resistance and possibly other cellular processes.
- the invention is based at least on the discovery that the life span of yeast cells can be extended by at least about 60% by increasing the flux through the nicotinamide adenine dinucleotide (NAD)+ salvage pathway (shown in Fig. 1).
- NAD nicotinamide adenine dinucleotide
- this increase in flux through the NAD+ salvage pathway occurs essentially without increase in NAD+ and NADH levels and essentially by maintaining the ratio of NAD+/NADH constant.
- increasing the flux through the NAD+ salvage pathway and thereby increasing the life span of cells can be achieved by introducing into the cells additional copies of a gene involved in the NAD+ salvage pathway, e.g., NPTl, PNCl, NMAl and NMA2.
- the invention is also based at least on the discovery that nicotinamide inhibits silencing in yeast and thereby decreases the life span of cells. Nicotinamide was also shown to render cells more sensitive to stress. In particular, it was shown that overexpression of nicotinamide methyl transferase (NNMT), an enzyme that is involved in the secretion of nicotinamide from cells, stimulated silencing and thus extended life span, and increased tolerance to stress (e.g., radiation exposure), whereas the deletion of this enzyme had the opposite effect.
- NNMT nicotinamide methyl transferase
- the methods of the invention are expected to be applicable to any eukaryotic cell, in addition to yeast cells, and to prokaryotic cells. 1. Definitions As used herein, the following terms and phrases shall have the meanings set forth below. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.
- isolated refers to molecules separated from other DNAs, or R As, respectively, that are present in the natural source of the macromolecule.
- isolated as used herein also refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.
- an isolated nucleic acid is meant to include nucleic acid fragments which are not naturally occurring as fragments and would not be found in the natural state.
- isolated is also used herein to refer to polypeptides which are isolated from other cellular proteins and is meant to encompass both purified and recombinant polypeptides.
- Modulating the flux through the NAD+ salvage pathway of a cell refers to an action resulting in increasing or decreasing the number of NAD+ molecules that are generated by the NAD+ salvage pathway, e.g. shown in Fig. 1.
- nucleic acid refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA).
- DNA deoxyribonucleic acid
- RNA ribonucleic acid
- the term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides.
- ESTs, chromosomes, cDNAs, mRNAs, and rRNAs are representative examples of molecules that may be referred to as nucleic acids.
- nucleic acid corresponding to a gene refers to a nucleic acid that can be used for detecting the gene, e.g., a nucleic acid which is capable of hybridizing specifically to the gene.
- percent identical refers to sequence identity between two amino acid sequences or between two nucleotide sequences. Identity can each be determined by comparing a position in each sequence which may be aligned for purposes of comparison.
- the molecules are identical at that position; when the equivalent site occupied by the same or a similar amino acid residue (e.g., similar in steric and/or electronic nature), then the molecules can be referred to as homologous (similar) at that position.
- Expression as a percentage of homology, similarity, or identity refers to a function of the number of identical or similar amino acids at positions shared by the compared sequences.
- Various alignment algorithms and/or programs may be used, including FASTA, BLAST, or ENTREZ.
- FASTA and BLAST are available as a part of the GCG sequence analysis package (University of Wisconsin, Madison, Wis.), and can be used with, e.g., default settings. ENTREZ is available through the National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Md.
- the percent identity of two sequences can be determined by the GCG program with a gap weight of 1, e.g., each amino acid gap is weighted as if it were a single amino acid or nucleotide mismatch between the two sequences.
- Other techniques for alignment are described in Methods in Enzymology, vol. 266: Computer Methods for Macromolecular Sequence Analysis (1996), ed.
- an alignment program that permits gaps in the sequence is utilized to align the sequences.
- the Smith- Waterman is one type of algorithm that permits gaps in sequence alignments. See Meth. Mol. Biol. 70: 173-187 (1997).
- the GAP program using the Needleman and Wunsch alignment method can be utilized to align sequences.
- An alternative search strategy uses MPSRCH software, which runs on a MASPAR computer.
- MPSRCH uses a Smith- Waterman algorithm to score sequences on a massively parallel computer. This approach improves ability to pick up distantly related matches, and is especially tolerant of small gaps and nucleotide sequence errors.
- Nucleic acid-encoded amino acid sequences can be used to search both protein and DNA databases. Databases with individual sequences are described in Methods in Enzymology, ed. Doolittle, supra. Databases include Genbank, EMBL, and DNA Database of Japan (DDBJ).
- Replicative life span which is used interchangeably herein with “life span” or “lifespan” of a cell refers to the number of daughter cells produced by an individual “mother cell.”
- Sir2 family members or “Sir2 protein family members” refers to S. cerevisiae
- Sir2 protein as well as any histone deacetylases having substantial structural similarities to Sir2, e.g., the human homologs hSIRTl, gSIRT2, hSIRT3, hSIRT4, hSIRT5, hSIRT ⁇ and hSIRT7; and Sir-2.1.
- Small molecule as used herein, is meant to refer to a composition, which has a molecular weight of less than about 5 kD and most preferably less than about 4 kD.
- Small molecules can be nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic (carbon-containing) or inorganic molecules.
- Many pharmaceutical companies have extensive libraries of chemical and/or biological mixtures, often fungal, bacterial, or algal extracts, which can be screened with any of the assays described herein.
- the term "specific hybridization" of a probe to a target site of a template nucleic acid refers to hybridization of the probe predominantly to the target, such that the hybridization signal can be clearly interpreted.
- Hybridization conditions will thus vary in the salt content, acidity, and temperature of the hybridization solution and the washes.
- Stress refers to any non-optimal condition for growth, development or reproduction.
- a “variant" of a polypeptide refers to a polypeptide having the amino acid sequence of the polypeptide in which is altered in one or more amino acid residues.
- the variant may have "conservative” changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine).
- a variant may have "nonconservative” changes (e.g., replacement of glycine with tryptophan).
- Analogous minor variations may also include amino acid deletions or insertions, or both.
- Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR). to about six carbon atoms in its backbone structure.
- “lower alkenyl” and “lower alkynyl” have similar chain lengths.
- heteroatom is art-recognized and refers to an atom of any element other than carbon or hydrogen.
- Illustrative heteroatoms include boron, nitrogen, oxygen, phosphorus, sulfur and selenium.
- aryl is art-recognized and refers to 5-, 6- and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pynole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like.
- aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles" or "heteroaromatics.”
- the aromatic ring may be substituted at one or more ring positions with such substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, -CF 3 , -CN, or the like.
- aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic, e.g., the other cyclic rings may be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.
- ortho. meta and para are art-recognized and refer to 1 ,2-, 1 ,3- and 1 ,4- disubstituted benzenes, respectively.
- the names 1 ,2-dimethylbenzene and ortho-dimefhylbenzene are synonymous.
- heterocyclyl or “heterocyclic group” are art-recognized and refer to 3- to about 10-membered ring structures, alternatively 3- to about 7-membered rings, whose ring structures include one to four heteroatoms. Heterocycles may also be polycycles.
- Heterocyclyl groups include, for example, thiophene, fhianfhrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxanthene, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanfhridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine,
- the heterocyclic ring may be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF , -CN, or the like.
- substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl
- polycyclyl or “polycyclic group” are art-recognized and refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are "fused rings". Rings that are joined through non-adjacent atoms are termed "bridged" rings.
- Each of the rings of the polycycle may be substituted with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF , -CN, or the like.
- the term "carbocycle” is art-recognized and refers to an aromatic or non-aromatic ring in which each atom of the ring is carbon.
- nitro is art-recognized and refers to -NO 2 ;
- halogen is art- recognized and refers to -F, -CI, -Br or -I;
- sulfhydryl is art-recognized and refers to -SH;
- hydroxyl means -OH;
- sulfonyl is art-recognized and refers to -SO 2 " .
- Halide designates the corresponding anion of the halogens, and
- amine and “amino” are art-recognized and refer to both unsubstituted and substituted amines, e.g., a moiety that may be represented by the general formulas:
- R50, R51 and R52 each independently represent a hydrogen, an alkyl, an alkenyl, - (CH 2 ) m -R61, or R50 and R51, taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure;
- R61 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and
- m is zero or an integer in the range of 1 to 8.
- only one of R50 or R51 may be a carbonyl, e.g., R50, R51 and the nitrogen together do not form an imide.
- R50, R51 and R52 may be a carbonyl, e.g., R50, R51 and the nitrogen together do not form an imide.
- R50, R51 and R52 may be a carbonyl, e.g., R50, R51 and the nitrogen together do not form an imide.
- variants when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to that of a particular gene or the coding sequence thereof. This definition may also include, for example, "allelic,” “splice,” “species,” or “polymorphic” variants.
- a splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing.
- the corresponding polypeptide may possess additional functional domains or an absence of domains.
- Species variants are polynucleotide sequences that vary from one species to another.
- polymorphic variantion is a variation in the polynucleotide sequence of a particular gene between individuals of a given species.
- Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.
- SNPs single nucleotide polymorphisms
- the term "aliphatic” is art-recognized and refers to a linear, branched, cyclic alkane, alkene, or alkyne. In certain embodiments, aliphatic groups in the present invention are linear or branched and have from 1 to about 20 carbon atoms.
- alkyl is art-recognized, and includes saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups.
- a straight chain or branched chain alkyl has about 30 or fewer carbon atoms in its backbone (e.g., C 1 -C 30 for straight chain, C 3 -C 30 for branched chain), and alternatively, about 20 or fewer.
- cycloalkyls have from about 3 to about 10 carbon atoms in their ring structure, and alternatively about 5, 6 or 7 carbons in the ring structure.
- alkyl is also defined to include halosubstituted alkyls.
- aralkyl is art-recognized and refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group).
- alkenyl and alkynyl are art-recognized and refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
- lower alkyl refers to an alkyl group, as defined above, but having from one to about ten carbons, alternatively from one
- lower alkenyl and “lower alkynyl” have similar chain lengths.
- heteroatom is art-recognized and refers to an atom of any element other than carbon or hydrogen.
- Illustrative heteroatoms include boron, nitrogen, oxygen, phosphorus, sulfur and selenium.
- aryl is art-recognized and refers to 5-, 6- and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like.
- aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles" or “heteroaromatics.”
- the aromatic ring may be substituted at one or more ring positions with such substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, -CF , -CN, or the like.
- aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic, e.g., the other cyclic rings maybe cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.
- ortho. meta and para are art-recognized and refer to 1 ,2-, 1 ,3- and 1 ,4- disubstituted benzenes, respectively.
- the names 1,2-dimefhylbenzene and ortho-dimethylbenzene are synonymous.
- heterocyclyl or “heterocyclic group” are art-recognized and refer to 3- to about 10-membered ring structures, alternatively 3- to about 7-membered rings, whose ring structures include one to four heteroatoms. Heterocycles may also be polycycles.
- Heterocyclyl groups include, for example, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxanthene, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, o
- the heterocyclic ring may be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF , -CN, or the like.
- substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl
- polycyclyl or “polycyclic group” are art-recognized and refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are "fused rings". Rings that are joined through non-adjacent atoms are termed "bridged" rings.
- Each of the rings of the polycycle may be substituted with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF 3 , -CN, or the like.
- the term "carbocycle” is art-recognized and refers to an aromatic or non-aromatic ring in which each atom of the ring is carbon.
- nitro is art-recognized and refers to -N0 2 ;
- halogen is art- recognized and refers to -F, -CI, -Br or -I;
- sulfhydryl is art-recognized and refers to -SH;
- hydroxyl means -OH;
- sulfonyl is art-recognized and refers to -SO 2 " .
- Halide designates the corresponding anion of the halogens, and
- amine and “amino” are art-recognized and refer to both unsubstituted and substituted amines, e.g., a moiety that may be represented by the general formulas:
- R50, R51 and R52 each independently represent a hydrogen, an alkyl, an alkenyl, - (CH 2 ) m -R61, or R50 and R51, taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure;
- R61 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and
- m is zero or an integer in the range of 1 to 8.
- only one of R50 or R51 may be a carbonyl, e.g., R50, R51 and the nitrogen together do not form an imide.
- R50, R51 and R52 may be a carbonyl, e.g., R50, R51 and the nitrogen together do not form an imide.
- R50, R51 and R52 may be a carbonyl, e.g., R50, R51 and the nitrogen together do not form an imide.
- alkylamine includes an amine group, as defined above, having a substituted or unsubstituted alkyl attached thereto, i.e., at least one of R50 and R51 is an alkyl group.
- acylamino is art-recognized and refers to a moiety that may be represented by the general formula:
- R50 wherein R50 is as defined above, and R54 represents a hydrogen, an alkyl, an alkenyl or - (CH 2 ) m -R61, where m and R61 are as defined above.
- amino is art recognized as an amino-substituted carbonyl and includes a moiety that may be represented by the general formula:
- alkylthio refers to an alkyl group, as defined above, having a sulfur radical attached thereto.
- the "alkylthio" moiety is represented by one of -S-alkyl, -S-alkenyl, -S-alkynyl, and -S-(CH 2 ) m -R61, wherein m and R61 are defined above.
- Representative alkylthio groups include methylthio, ethyl thio, and the like.
- carbonyl is art recognized and includes such moieties as may be represented by the general formulas:
- X50 is a bond or represents an oxygen or a sulfur
- R55 and R56 represents a hydrogen, an alkyl, an alkenyl, -(CH 2 ) m -R61or a pharmaceutically acceptable salt
- R56 represents a hydrogen, an alkyl, an alkenyl or -(CH 2 ) m -R61, where m and R61 are defined above.
- X50 is an oxygen and R55 or R56 is not hydrogen, the formula represents an
- alkoxyl or "alkoxy” are art-recognized and refer to an alkyl group, as defined above, having an oxygen radical attached thereto.
- Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like.
- An "ether” is two hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as may be represented by one of -O-alkyl, -O-alkenyl, -O-alkynyl, -0 ⁇ (CH 2 ) m -R61, where m and R61 are described above.
- each expression e.g. alkyl, m, n, and the like, when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.
- triflyl, tosyl, mesyl, and nonaflyl are art-recognized and refer to trifluoromethanesulfonyl,/7-toluenesulfonyl, methanesulfonyl, and nonafluorobutanesulfonyl groups, respectively.
- triflate, tosylate, mesylate, and nonaflate are art-recognized and refer to trifluoromethanesulfonate ester, »-toluenesulfonate ester, methanesulfonate ester, and nonafluorobutanesulfonate ester functional groups and molecules that contain said groups, respectively.
- Me, Et, Ph, Tf, Nf, Ts, and Ms represent methyl, ethyl, phenyl, trifluoromefhanesulfonyl, nonafluorobutanesulfonyl, /j-toluenesulfonyl and methanesulfonyl, respectively.
- a more comprehensive list of the abbreviations utilized by organic chemists of ordinary skill in the art appears in the first issue of each volume of the Journal of Organic Chemistry; this list is typically presented in a table entitled Standard List of Abbreviations.
- compositions of the present invention may exist in particular geometric or stereoisomeric forms.
- polymers of the present invention may exist in particular geometric or stereoisomeric forms.
- - 24 may also be optically active.
- the present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)- isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
- a particular enantiomer of compound of the present invention may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers.
- the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.
- substitution or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
- substituted is also contemplated to include all permissible substituents of organic compounds.
- the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds.
- Illustrative substituents include, for example, those described herein above.
- the permissible substituents may be one or more and the same or different for appropriate organic compounds.
- the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds.
- hydrocarbon is contemplated to include all permissible compounds having at least one hydrogen and one carbon atom.
- the permissible hydrocarbons include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic organic compounds that may be substituted or unsubstituted.
- the definition of each expression, e.g. lower alkyl, m, n, p and the like, when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.
- pharmaceutically-acceptable salts refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds, including, for example, those contained in compositions of the present invention.
- pharmaceutically acceptable carrier refers to a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof from one organ, or portion of the body, to another organ, or portion of the body.
- a pharmaceutically-acceptable material such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier must be “acceptable” in the sense of being compatible with the subject composition and its components and not injurious to the patient.
- materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide;
- systemic administration refers to the administration of a subject composition, therapeutic or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
- parenteral administration and “administered parenterally” are art- recognized and refer to modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articulare, subcapsular, subarachnoid, intraspinal, and intrasternal injection and infusion. 2. Methods for increasing the life span of a cell or protecting it against certain stresses
- the life span of a cell is increased and/or the cell is protected against certain stresses by increasing the flux through the NAD+ salvage pathway. This can be achieved, e.g., increasing the level or activity of at least one protein involved in the NAD+ salvage pathway, such as a protein selected from the group consisting of NPTl, PNC 1, NMAl and NMA2.
- the level of protein can be increased in a cell, e.g., by introducing into the cell a nucleic acid encoding the protein operably linked to a transcriptional regulatory sequence directing the expression of the protein in the cell.
- a protein can be introduced into a cell, usually in the presence of a vector facilitating the entry of the protein into the cells, e.g., liposomes. Proteins can also be linked to transcytosis peptides for that purpose.
- an agent that stimulates expression of the endogenous gene is contacted with a cell. Such agents can be identified as further described herein.
- NPTl S. cerevisiae nicotinate phosphoribosyltransferase
- LSR2 The S. cerevisiae NPTl complete cDNA and encoded protein are provided by GenBank Accession numbers NC_001147 and AAB59317, respectively, which are set forth as SEQ ID NOs: 1 and 2, respectively. Accession numbers LI 1274 and AAB59317 also appear to refer to S. cerevisiae nucleotide and amino acid sequences, respectively.
- the NPTl homolog in bacteria is PncB (35, 37 and 38).
- colx NPTl is provided as GenBank accession number J05568.
- the human nucleotide and amino acid sequences are provided by GenBank Accession numbers BC006284 and AAH06284, respectively, and X71355 and CAA50490, respectively, AAH32466 and BC032466 and are described in Chong et al. (1993) Genomics 18:355.
- the human nucleotide and amino acid sequences are also set forth as SEQ ID NOs: 13 and
- NPTl nucleotide and amino acid sequences are provided by GenBank Accession numbers X77241 and CAA54459 and are described in Chong et al. (1995) Am. J. Physiol. 268: 1038.
- the promoter region of mouse NPTl is provided as GenBank Accession number AF361762 and is described in Soumounou et al. (2001) Am J. Physiol. 281 : F1082.
- NPTl is also set forth as an IMAGE Clone, under number 3957135.
- An alignment of NPTl homologs is set forth in Fig. 15.
- a nucleotide sequence encoding S. cerevisiae PNCl and the protein encoded thereby are set forth as SEQ ID Nos: 3 and 4, respectively, which correspond to GenBank Accession numbers NC_001139 and NP_011478, respectively.
- PNCl is the yeast homologue of the bacterial protein pncA, which catalyzes the hydrolysis of nicotinamide to nicotinic acid and ammonia.
- S. cerevisiae PNCl also referred to as open reading frame (ORF) YGL037 is described in Ghislain et al. (2002) Yeast 19:215.
- nucleotide and amino acid sequences of an Arachis hypogaea PNC 1 is provided by GenBank Accession numbers M37636 and AAB06183 and are described in Buffard et al. (1990) PNAS 87:8874.
- Nucleotide and amino acid sequences of a human homolog are provided by GenBank Accession numbers BC017344 and AAH17344, respectively; AK027122 and NP 078986, respectively; XM_041059 and XP_041059, respectively; and NM_016048 and NP_057132, respectively.
- the nucleotide and amino acid sequences of human PNCl are set forth as SEQ ID NOs: 15 and 16, respectively and correspond to GenBank Accession No. BC017344.
- An alignment of human, fly and S. cerevisiae PNCl is set forth in Fig. 16.
- a nucleotide sequence encoding S. cerevisae NMAl and the protein encoded thereby are set forth as SEQ ID Nos: 5 and 6, respectively, which correspond to GenBank Accession Numbers NC_001144.2 and NP 013432, respectively.
- the S. cerevisiae NMAl corresponds to ORF YLR328, described in Smith et al. (2000) PNAS 97:6658.
- NMAl is the S. cerevisae homolog of the bacterial NaMNAT gene.
- Nucleotide and amino acid sequences of human homologs are provided by GenBank Accession numbers NM 022787 and NP_073624, respectively; AK026065 and BAB 15345, respectively;
- S. cerevisiae NMA2 corresponds to ORF YGR010, described in Emanuelli et al.
- NMA2 is the S. cerevisiae homolog of the bacterial NaMNAT gene. Nucleotide and amino acid sequences of human homologs are provided by GenBank Accession numbers NM 015039 and NP_055854, respectively. The nucleotide and amino acid sequences of human NMA2 are set forth as SEQ ID NOs: 19 and 20, respectively, and correspond to GenBank Accession number NM 015039.
- a portion of a protein is preferably a biologically active portion thereof. Portions that are biologically active can be identified according to methods known in the art and using an assay that can monitor the activity of the particular protein. Assays for determining the activity of an NPTl protein are described, e.g., in Pescanglini et al. (1994) Clin. Chim. Acta 229: 15-25 and Sestini et al. (2000) Archives of Biochem. Biophys. 379:277. Assays for determining the activity of a PNCl protein are described, e.g., in
- NMAl and NMA2 protein Assays for determining the activity of an NMAl and NMA2 protein are described, e.g., in Sestini et al., supra. Alternatively, the activity of such a protein can be tested in an assay in which the life span of a cell is determined. For example, a cell is transfected with a nucleic acid comprising one or more copies of a sequence encoding a portion of an NPT 1 , PNC 1 , NMA 1 or NMA2 protein or a control nucleic acid, and the life span of the cells is compared.
- a longer life span of a cell transfected with a portion of one of the proteins indicates that the portion of the protein is a biologically active portion.
- Assays for determining the life span of a cell are known in the art and are also further described herein. In particular, assays for determining the life span of a mammalian cell can be conducted as described, e.g., in Cell Growth, Differentiation and Senescence: A Practical Approach. George P. Studzinski (ed.). Instead of measuring the life span, one can also measure the resistance of a transfected cell to certain stresses, e.g., heatshock, for determining whether a portion of a protein is a biologically active
- Proteins encoded by nucleic acids that hybridize to a nucleic acid encoding NPTl, PNCl, NMAl or NMA2 under high or medium stringency conditions and which are biologically active can also be used.
- nucleic acids that hybridize under high stringency conditions of 0.2 to 1 x SSC at 65 °C followed by a wash at 0.2 x SSC at 65 °C to a gene encoding NPTl, PNCl, NMAl or NMA2 can be used.
- Nucleic acids that hybridize under low stringency conditions of 6 x SSC at room temperature followed by a wash at 2 x SSC at room temperature to a gene encoding NPTl , PNCl , NMAl or NMA2 can be used.
- hybridization conditions include 3 x SSC at 40 or 50 °C, followed by a wash in 1 or 2 x SSC at 20, 30, 40, 50, 60, or 65 °C.
- Hybridizations can be conducted in the presence of formaldehyde, e.g., 10%, 20%, 30% 40% or 50%, which further increases the stringency of hybridization. Theory and practice of nucleic acid hybridization is described, e.g., in S.
- Exemplary proteins may have at least about 50%>, 70%, 80%>, 90%, preferably at least about 95%, even more preferably at least about 98% and most preferably at least 99% homology or identity with a wild-type NPTl, PNCl, NMAl or NMA2 protein or a domain thereof, e.g., the catalytic domain.
- exemplary proteins may be encoded by a nucleic acid that is at least about 90%>, preferably at least about 95%, even more preferably at least about 98% and most preferably at least 99% homology or identity with a wild-type NPTl , PNCl, NMAl or NMA2 nucleic acid, e.g., those described herein.
- proteins are fusion proteins, e.g., proteins fused to a transcytosis peptide. Fusion proteins may also comprise a heterologous peptide that can be used to purify the protein and/or to detect it.
- non-naturally occurring protein variants are used.
- Such variants can be peptidomimetics.
- the activity of one or more proteins selected from the group consisting of NPTl, PNCl, NMAl and NMA2 is enhanced or increased. This can be achieved, e.g., by contacting a cell with a compound that increases the activity, e.g., enzymatic activity, of one of these proteins. Assays for identifying such compounds are further described herein.
- the flux through the NAD+ salvage pathway is increased without substantially changing the level of NAD+, NADH and the ratio of NAD+/NADH in a cell.
- Levels of NAD+ and NADH and ratios of these two molecules can be determined, e.g., as described in the Examples. Any means for the introduction of polynucleotides into mammals, human or non- human, or cells thereof may be adapted to the practice of this invention for the delivery of the various constructs of the invention into the intended recipient.
- the DNA constructs are delivered to cells by transfection, i.e., by delivery of "naked" DNA or in a complex with a colloidal dispersion system.
- a colloidal system includes macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
- the preferred colloidal system of this invention is a lipid-complexed or liposome-formulated DNA.
- a plasmid containing a transgene bearing the desired DNA constructs may first be experimentally optimized for expression (e.g., inclusion of an intron in the 5' untranslated region and elimination of unnecessary sequences (Feigner, et al., Ann NY Acad Sci 126-139, 1995).
- Formulation of DNA e.g.
- lipid or liposome materials may then be effected using known methods and materials and delivered to the recipient mammal. See, e.g., Canonico et al, Am J Respir Cell Mol Biol 10:24-29, 1994; Tsan et al, Am J Physiol 268; Alton et al., Nat Genet. 5: 135-142, 1993 and U.S. patent No. 5,679,647 by Carson et al.
- the targeting of liposomes can be classified based on anatomical and mechanistic factors. Anatomical classification is based on the level of selectivity, for example, organ- specific, cell-specific, and organelle-specific. Mechanistic targeting can be distinguished
- Passive targeting utilizes the natural tendency of liposomes to distribute to cells of the reticulo-endothelial system (RES) in organs, which contain sinusoidal capillaries.
- Active targeting involves alteration of the liposome by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein, or by changing the composition or size of the liposome in order to achieve targeting to organs and cell types other than the naturally occurring sites of localization.
- the surface of the targeted delivery system may be modified in a variety of ways.
- lipid groups can be incorporated into the lipid bilayer of the liposome in order to maintain the targeting ligand in stable association with the liposomal bilayer.
- Various linking groups can be used for joining the lipid chains to the targeting ligand. Naked DNA or DNA associated with a delivery vehicle, e.g., liposomes, can be administered to several sites in a subject (see below).
- the DNA constructs are delivered using viral vectors.
- the transgene may be incorporated into any of a variety of viral vectors useful in gene therapy, such as recombinant retroviruses, adenovirus, adeno-associated virus (AAV), and herpes simplex virus- 1, or recombinant bacterial or eukaryotic plasmids. While various viral vectors may be used in the practice of this invention, AAV- and adenovirus-based approaches are of particular interest. Such vectors are generally understood to be the recombinant gene delivery system of choice for the transfer of exogenous genes in vivo, particularly into humans. The following additional guidance on the choice and use of viral vectors may be helpful to the practitioner.
- a viral gene delivery system useful in the present invention utilizes adenovirus- derived vectors.
- Knowledge of the genetic organization of adenovirus, a 36 kB, linear and double-stranded DNA virus, allows substitution of a large piece of adeno viral DNA with foreign sequences up to 8 kB.
- retrovirus the infection of adenoviral DNA into host cells does not result in chromosomal integration because adenoviral DNA can replicate in an episomal manner without potential genotoxicity.
- adenoviruses are structurally stable, and no genome rearrangement has been detected after extensive amplification. Adenovirus can infect virtually all epithelial cells regardless of their cell
- adenoviral infection appears to be linked only to mild disease such as acute respiratory disease in the human.
- Adenovirus is particularly suitable for use as a gene transfer vector because of its mid-sized genome, ease of manipulation, high titer, wide target-cell range, and high infectivity.
- the virus particle is relatively stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of infectivity.
- adenovirus is easy to grow and manipulate and exhibits broad host range in vitro and in vivo. This group of viruses can be obtained in high titers, e.g., 10 9 - 10 1 ' plaque-forming unit (PFU)/ml, and they are highly infective.
- PFU plaque-forming unit
- the foreign genes delivered by adenovirus vectors are episomal, and therefore, have low genotoxicity to host cells. No side effects have been reported in studies of vaccination with wild-type adenovirus (Couch et al., 1963; Top et al., 1971), demonstrating their safety and therapeutic potential as in vivo gene transfer vectors. Moreover, the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors (Berkner et al., supra; Haj-Ahmand and Graham (1986) J. Virol. 57:267).
- adenoviral vectors currently in use and therefore favored by the present invention are deleted for all or parts of the viral El and E3 genes but retain as much as 80% of the adenoviral genetic material (see, e.g., Jones et al., (1979) Cell 16:683; Berkner et al., supra; and Graham et al., in Methods in Molecular Biology, E.J. Murray, Ed. (Humana, Clifton, NJ, 1991) vol. 7. pp. 109-127).
- Expression of the inserted polynucleotide of the invention can be under control of, for example, the El A promoter, the major late promoter (MLP) and associated leader sequences, the viral E3 promoter, or exogenously added promoter sequences.
- MLP major late promoter
- the genome of an adenovirus can be manipulated such that it encodes a gene product of interest, but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle (see, for example, Berkner et al., (1988) BioTechniques 6:616; Rosenfeld et al., (1991) Science 252:431-434; and Rosenfeld et al., (1992) Cell 68:143-155).
- Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus are well known to those skilled in the art.
- Recombinant adenoviruses can be advantageous in certain circumstances in that they are not capable of infecting nondividing cells and can be used to infect a wide variety of cell types, including airway epithelium (Rosenfeld et al., (1992) cited supra), endothelial cells
- Adenoviruses can also be cell type specific, i.e., infect only restricted types of cells and/or express a transgene only in restricted types of cells.
- the viruses comprise a gene under the transcriptional control of a transcription initiation region specifically regulated by target host cells, as described e.g., in U.S. Patent No. 5,698,443, by Henderson and Schuur, issued December 16, 1997.
- replication competent adenoviruses can be restricted to certain cells by, e.g., inserting a cell specific response element to regulate a synthesis of a protein necessary for replication, e.g., El A or E1B.
- DNA sequences of a number of adenovirus types are available from Genbank.
- human adenovirus type 5 has GenBank Accession No.M73260.
- the adenovirus DNA sequences may be obtained from any of the 42 human adenovirus types currently identified.
- Various adenovirus strains are available from the American Type Culture Collection, Rockville, Maryland, or by request from a number of commercial and academic sources.
- a transgene as described herein may be inco ⁇ orated into any adenoviral vector and delivery protocol, by restriction digest, linker ligation or filling in of ends, and ligation.
- Adenovirus producer cell lines can include one or more of the adenoviral genes El, E2a, and E4 DNA sequence, for packaging adenovirus vectors in which one or more of these genes have been mutated or deleted are described, e.g., in PCT/US95/15947 (WO 96/18418) by Kadan et al.; PCT/US95/07341 (WO 95/346671) by Kovesdi et al.; PCT/FR94/00624 (WO94/28152) by Imler et al.;PCT/FR94/00851 (WO 95/02697) by Perrocaudet et al., PCT/US95/14793 (WO96/14061) by Wang et al.
- Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle.
- AAV has not been associated with the cause of any disease.
- AAV is not a transforming or oncogenic virus.
- AAV integration into chromosomes of human cell lines does not cause any significant alteration in the growth properties or mo ⁇ hological characteristics of the cells. These properties of AAV also recommend it as a potentially useful human gene therapy vector.
- AAV is also one of the few viruses that may integrate its DNA into non-dividing cells, e.g., pulmonary epithelial cells, and exhibits a high frequency of stable integration (see for example Flotte et al., (1992) Am. J. Respir. Cell. Mol. Biol. 7:349-356; Samulski et al., (1989) J. Virol. 63:3822-3828; and McLaughlin et al., (1989) J. Virol. 62:1963-1973).
- Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. Space for exogenous DNA is limited to about 4.5 kb.
- An AAV vector such as that described in Tratschin et al., (1985) Mol. Cell. Biol. 5:3251-3260 can be used to introduce DNA into cells.
- a variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example Hermonat et al., (1984) PNAS USA 81:6466-6470; Tratschin et al., (1985) Mol. Cell. Biol. 4:2072-2081; Wondisford et al., (1988) Mol.
- the AAV-based expression vector to be used typically includes the 145 nucleotide AAV inverted terminal repeats (ITRs) flanking a restriction site that can be used for subcloning of the transgene, either directly using the restriction site available, or by excision of the transgene with restriction enzymes followed by blunting of the ends, ligation of appropriate DNA linkers, restriction digestion, and ligation into the site between the ITRs.
- ITRs inverted terminal repeats
- the capacity of AAV vectors is about 4.4 kb (Kotin, R.M., Human Gene Therapy 5:793-801, 1994 and Flotte, et al. J. Biol.Chem. 268:3781-3790, 1993).
- AAV stocks can be produced as described in Hermonat and Muzyczka (1984)
- PNAS 81 :6466 modified by using the pAAV/Ad described by Samulski et al. (1989) J. Virol. 63:3822.
- Concentration and purification of the virus can be achieved by reported methods such as banding in cesium chloride gradients, as was used for the initial report of AAV vector expression in vivo (Flotte, et al. J.Biol. Chem. 268:3781-3790, 1993) or chromatographic purification, as described in O'Riordan et al., WO97/08298.
- Methods for in vitro packaging AAV vectors are also available and have the advantage that there is no size limitation of the DNA packaged into the particles (see, U.S. Patent No.
- Hybrid Adenovirus- AAV vectors represented by an adenovirus capsid containing a nucleic acid comprising a portion of an adenovirus, and 5' and 3' ITR sequences from an AAV which flank a selected transgene under the control of a promoter. See e.g. Wilson et al, International Patent Application Publication No. WO 96/13598.
- This hybrid vector is
- This virus is capable of infecting virtually all cell types (conferred by its adenovirus sequences) and stable long term transgene integration into the host cell genome (conferred by its AAV sequences).
- adenovirus nucleic acid sequences employed in this vector can range from a minimum sequence amount, which requires the use of a helper virus to produce the hybrid virus particle, to only selected deletions of adenovirus genes, which deleted gene products can be supplied in the hybrid viral process by a packaging cell.
- a hybrid virus can comprise the 5' and 3' inverted terminal repeat (ITR) sequences of an adenovirus
- the left terminal sequence (5') sequence of the Ad5 genome that can be used spans bp 1 to about 360 of the conventional adenovirus genome (also referred to as map units 0-1) and includes the 5' ITR and the packaging/enhancer domain.
- the 3' adenovirus sequences of the hybrid virus include the right terminal 3' ITR sequence which is about 580 nucleotides (about bp 35,353- end of the adenovirus, referred to as about map units 98.4-100).
- hybrid vector The preparation of the hybrid vector is further described in detail in published PCT application entitled "Hybrid Adenovirus-AAV Virus and Method of Use Thereof, WO 96/13598 by Wilson et al.
- adenovirus and hybrid adenovirus-AAV technology which may be useful in the practice of the subject invention, including methods and materials for the inco ⁇ oration of a transgene, the propagation and purification of recombinant virus containing the transgene, and its use in transfecting cells and mammals, see also Wilson et al, WO 94/28938, WO 96/13597 and WO 96/26285, and references cited therein.
- a nucleic acid of interest is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication- defective.
- a packaging cell line containing the gag, pol, and env genes but without the LTR and psi components is constructed (Mann et al. (1983) Cell 33: 153).
- a recombinant plasmid containing a human cDNA, together with the retroviral LTR and psi sequences is introduced into this cell line (by calcium phosphate precipitation for example), the psi sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media (Nicolas and Rubenstein (1988) "Retroviral Vectors", In: Rodriguez and Denhardt ed.
- Retroviral vectors are able to infect a broad variety of cell types. Integration and stable expression require the division of host cells (Paskind et al. (1975) Virology 67:242).
- This aspect is particularly relevant for the treatment of PVR, since these vectors allow selective targeting of cells which proliferate, i.e., selective targeting of the cells in the epiretinal membrane, since these are the only ones proliferating in eyes of PVR subjects.
- a major prerequisite for the use of retroviruses is to ensure the safety of their use, particularly with regard to the possibility of the spread of wild-type virus in the cell population.
- the development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased the utility of retroviruses for gene therapy, and defective retroviruses are well characterized for use in gene transfer for gene therapy pu ⁇ oses (for a review see Miller, A.D. (1990) Blood 76:271).
- recombinant retrovirus can be constructed in which part of the retroviral coding sequence (gag, pol, env) has been replaced by nucleic acid encoding a protein of the present invention, e.g., a transcriptional activator, rendering the retrovirus replication defective.
- the replication defective retrovirus is then packaged into virions which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F.M.
- retroviruses examples include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art.
- a prefened retroviral vector is a pSR MSVtkNeo (Muller et al. (1991) Mol. Cell Biol. 11 : 1785 and pSR MSV(Xbal) (Sawyers et al. (1995) J. Exp. Med. 181 :307) and derivatives thereof.
- the unique BamHI sites in both of these vectors can be removed by digesting the vectors with BamHI, filling in with Klenow and religating to produce pSMTN2 and pSMTX2, respectively, as described in PCT/US96/09948 by Clackson et al.
- suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include Crip, Cre, 2 and Am.
- Retroviruses including lentiviruses, have been used to introduce a variety of genes into many different cell types, including neural cells, epithelial cells, retinal cells, endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, in vitro and/or in vivo (see for example, review by Federico (1999) Curr. Opin. Biotechnol.
- retroviral-based vectors it has been shown that it is possible to limit the infection spectrum of retroviruses and consequently of retroviral-based vectors, by modifying the viral packaging proteins on the surface of the viral particle (see, for example PCT publications WO93/25234, WO94/06920, and WO94/11524).
- strategies for the modification of the infection spectrum of retroviral vectors include: coupling antibodies specific for cell surface antigens to the viral env protein (Roux et al, (1989) PNAS USA 86:9079-9083; Julan et al, (1992) J.
- Coupling can be in the form of the chemical cross-linking with a protein or other variety (e.g. lactose to convert the env protein to an asialoglycoprotein), as well as by generating fusion proteins (e.g. single-chain antibody/env fusion proteins).
- This technique while useful to limit or otherwise direct the infection to certain tissue types, and can also be used to convert an ecotropic vector in to an amphotropic vector.
- viral vector systems that can be used to deliver a polynucleotide of the invention have been derived from he ⁇ es virus, e.g., He ⁇ es Simplex Virus (U.S. Patent No. 5,631,236 by Woo et al, issued May 20, 1997 and WO 00/08191 by Neurovex), vaccinia virus (Ridgeway (1988) Ridgeway, "Mammalian expression vectors," In: Rodriguez R L, Denhardt D T, ed. Vectors: A survey of molecular cloning vectors and their uses. Stoneham: Butterworth,; Baichwal and Sugden (1986) "Vectors for gene transfer derived
- RNA viruses include an alpha virus, a poxivirus, an arena virus, a vaccinia virus, a polio virus, and the like. They offer several attractive features for various mammalian cells (Friedmann (1989) Science, 244: 1275-1281 ;
- a protein e.g., a protein selected from the group consisting of NPTl, PNCl, NMAl and NMA2 or a biologically active variant thereof in cells of a subject to whom, e.g., a nucleic acid encoding the protein was administered, can be determined, e.g., by obtaining a sample of the cells of the patient and determining the level of the protein in the sample, relative to a control sample.
- a protein or biologically active variant thereof is administered to the subject such that it reaches the target cells, and traverses the cellular membrane.
- Polypeptides can be synthesized in prokaryotes or eukaryotes or cells thereof and purified according to methods known in the art. For example, recombinant polypeptides can be synthesized in human cells, mouse cells, rat cells, insect cells, yeast cells, and plant cells. Polypeptides can also be synthesized in cell free extracts, e.g., reticulocyte lysates or wheat germ extracts.
- the polypeptide is produced as a fusion polypeptide comprising an epitope tag consisting of about six consecutive histidine residues.
- the fusion polypeptide can then be purified on a Ni ++ column.
- the tag By inserting a protease site between the tag and the polypeptide, the tag can be removed after purification of the peptide on the Ni ⁇ column.
- polypeptides can be done by mixing them with liposomes, as described above.
- the surface of the liposomes can be modified by adding molecules that will target the liposome to the desired physiological location.
- a protein is modified so that its rate of traversing the cellular membrane is increased.
- the polypeptide can be fused to a second peptide which promotes "transcytosis," e.g., uptake of the peptide by cells.
- the peptide is a portion of the HIV transactivator (TAT) protein, such as the fragment
- the internalizing peptide is derived from the Drosophila antennapedia protein, or homologs thereof.
- the 60 amino acid long homeodomain of the homeo-protein antennapedia has been demonstrated to translocate through biological membranes and can facilitate the translocation of heterologous polypeptides to which it is couples.
- polypeptides can be fused to a peptide consisting of about amino acids 42-58 of Drosophila antennapedia or shorter fragments for transcytosis. See for example Derossi et al. (1996) J Biol Chem 271:18188-18193; Derossi et al. (1994) J Biol Chem 269:10444-10450; and Perez et al. (1992) J Cell Sci 102:717-722.
- the amount of nicotinamide is decreased in a cell.
- This can be achieved, e.g, by inhibiting the expression of genes of the NAD+ salvage pathway or other pathway that produce nicotinamide. Inhibition of the genes can be conducted, e.g, as further described herein, such as by performing RNAi on the NAD+ salvage pathway genes that produce nicotinamide.
- One can also inhibit genes that are involved in the de novo synthesis of nicotinamide.
- nicotinamide levels in cells can be regulated by regulating the level or activity of poly(adenosine diphosphate-ribose) polymerase- 1 (PARP).
- PARP poly(adenosine diphosphate-ribose) polymerase- 1
- nicotinamide levels can be reduced by reducing the level or activity of PARP, since this enzyme generates nicotinamide.
- Nicotinamide levels may also be decreased in cells by reducing the level or activity of glycohydrolases (e.g, human CD38, an ectoenzyme that is expressed on the surface of immune cells, such as neutrophils; gi:4502665 and GenBank Accession No. NP_001766), which cleave NAD to nicotinamide.
- glycohydrolases e.g, human CD38, an ectoenzyme that is expressed on the surface of immune cells, such as neutrophils; gi:4502665 and GenBank Accession No. NP_001766
- Nicotinamide levels may also be decreased by inhibiting the de novo nicotinamide synthesis pathway. Genes involved in this pathway include the BNA genes in S. cerevisiae (BNA1-6). Alternatively, poly(adenosine diphosphate-ribose) polymerase (PARP) family members, e.g, PARP-1 and PARPv and tankyrase can also be inhibited to decrease nicotinamide levels.
- PARP poly(adenosine diphosphate-ribose) polymerase
- nicotinamide transporters it is also possible to reduce the level or activity of nicotinamide transporters to reduce the level of nicotinamide that is imported into cells.
- nicotinic acid is transported by the Tnal (nicotinate/nicotinamide mononucleotide transport) protein.
- Human homologues of yeast TNA1 have the following GenBank Accession numbers: gi:9719374 and AAF97769; gi:6912666 and NP_036566; gi: 18676562 and AB84933;
- nucleoside transporters that can be modulated include bacterial and fly nucleoside transporter and the following human genes that are homologous thereto: gi:8923160 and NP_060164; gi: 14336678 and AAK61212; gi: 22749231 and NP_689812; and gi: 18603939 and XP_091525.
- nicotinamide levels can be decreased or nicotinamide inactivated, e.g, by stimulating the activity or increase the level of enzymes that metabolize, degrade or inhibit nicotinamide, e.g, nicotinamide N-methyl transferase, also referred to as nicotinamide methyltransferase (NNMT; EC 2.1.1.1; CAS registry number 9029-74-7).
- nicotinamide N-methyl transferase also referred to as nicotinamide methyltransferase (NNMT; EC 2.1.1.1; CAS registry number 9029-74-7).
- the human enzyme is referred to as NNMT and its complete sequence can be found at GenBank Accession number U08021 and as SEQ ID NO: 9 for the nucleotide sequence and SEQ ID NO: 10 for the protein (Aksoy et al. (1994) J. Biol. Chem. 269: 14835 ).
- the yeast version of this enzyme is referred to as NNT1 (also referred to as YLR258w).
- NAMPRT nicotinamide phosphribosyltransferase
- the human gene is also referred to as pre-B-cell colony enhancing factor (PBEF), and its sequence is available under GenBank Accession numbers NP_005737; NM_005746; AAH20691; and BC020691.
- PBEF pre-B-cell colony enhancing factor
- the nucleotide and amino acid sequences of human NAMPRT (BC020691) are set forth as SEQ ID NOs: 11 and 12, respectively.
- yeast and human cells the level of NPTl or human homolog thereof, respectively, can be increased to reduce nicotinamide levels.
- NMN nicotinamide mononucleotide
- GenBank Accession numbers are provided for the human enzyme: NP_073624; NM_022787; AAL76934; AF459819; and NP_073624; AF314163.
- NMNAT-2 (KIAA0479), the human version of which can be found under GenBank Accession numbers NP_055854 and NM 015039 (Raffaelli et al. (2002) Biochem Biophys Res Commun 297:835).
- yeast cells the equivalent enzymes in
- NAD+ salvage pathway are nicotinate mononucleotide adenyltransferase 1 and 2 (NMAl and NMA2, respectively) (E.C. 2.7.7.1).
- PRPP phosphoribosyl pyrophosphate
- PRPS phosphoribosyl pyrophosphate
- GenBank Accession numbers gi:4506127 and NP_002755 (P ⁇ sl); gi:4506129 and NP_002756 (P ⁇ s2); gi:20539448; gi:4506133 and NP_002758 (P ⁇ s associated protein 2); gi:24418495 and Q14558 (P ⁇ s associated protein 1); gi:17644236 and CAD18892; gi:2160401 and BAA05675 (P ⁇ s isoform 1); and gi:2160402 and BAA05676 (P ⁇ s isoform 2).
- nicotinamide negatively regulates PARP.
- regulating the level of nicotinamide in cells e.g, as further described herein, will regulate the activity of PARP.
- modulating nicotinamide levels will modulate these activities. For example, reducing nicotinamide levels in cells will increase the activity of PARP and thereby further enhance the DNA break repair mechanism of cells.
- the methods can also be applied to plant cells, based at least on the fact that Sir2 family members are present in plants. Accordingly, the invention also provides methods for extending the life span of plants and plant cells and for rendering the plant and plant cells more resistant to stress, e.g, excessive salt conditions. This can be achieved, e.g, by modulating the level or activity of proteins in the plant cells that are essentially homologous to the proteins described herein in the yeast and mammalian systems as increasing the life span and/or the stress resistance of cells.
- the level of nicotinamide in plant cells can be reduced, in particular, as described herein for modulating their level in other eukaryotic cells.
- Nucleic acids can be introduced into plant cells according to methods known in the art. For example, the following are genes form Arabidopsis thalainia that are homologous to the genes described above that can be modulated to modulate the flux throught the NAD+ salvage pathway or nicotinamide levels in cells. Homologues of yeast PNCl: gi 18401044 NP_566539.1 (a putative hydrolase); gi 15237256 NP_1977131; and gi
- yeast NPTl gi 2026021 AAM13003.1; gi 15234571 NP_195412.1 ; gi 25054896 AAN71931.1; and gi 15227832 NP_179923.1.
- yeast NMA1/2 gi 22327861 NP_200392.2 and gi 9758615 BAB09248.1.
- yeast NNT1 Homologues of yeast NNT1 (YL285W): gi 20197178 AAC14529; gi 22325900 NP_565619.2; gi 15219438 NP 77475.1 (a Tumor related Protein); gi 12324311 AA652120.1; gi:22330409 NP_683465; gi:15240506 NP_199767; gi 8778835 AAF79834.1; and gi 15231011 NP 88637.
- Homologue of human NNMT Homologue of human NNMT: gi 15238203 NP_196623.
- yeast QNS1 gene downstream of NMAl 12 in the NAD+ salvage pathway
- yeast BNA6 gi:18379203 NP_565259 and gi:21555686 AAM63914.
- the methods of the invention can also be used to increase the lifespan and stress resistance in microorganisms, such as prokaryotes, based on the fact that Sir2 family members are also present in these organisms. 3. Methods for reducing the life span of a cell or rendering it more susceptible to certain stresses
- the level of expression or activity of a protein selected from the group consisting of NPTl, PNCl, NMAl and NMA2 is decreased in a cell.
- an agent that inhibits the expression of the corresponding gene can be a small molecule that acts directly or indirectly on the promoter of the corresponding gene to reduce or inhibit its transcription.
- An agent can also be a compound that inhibits the biological activity of the protein.
- An agent can also be an antisense molecule, a triplex molecule or a si RNA.
- Yet other agents are nucleic acids encoding a protein, such as a dominant negative mutant or an intracellular antibody or other protein that interferes with the biological activity of the protein. Such methods are well known in the art. Exemplary methods are set forth below.
- One method for decreasing the level of expression of a gene in a cell is to introduce into the cell antisense molecules which are complementary to at least a portion of the target gene or RNA.
- An "antisense”nucleic acid as used herein refers to a nucleic acid capable of hybridizing to a sequence-specific (e.g, non-poly A) portion of the target RNA, for example its translation initiation region, by virtue of some sequence complementarity to a coding and/or non-coding region.
- the antisense nucleic acids of the invention can be oligonucleotides that are double-stranded or single-stranded, RNA or DNA or a modification or derivative thereof, which can be directly administered in a controllable
- antisense nucleic acids are of at least six nucleotides and are preferably oligonucleotides (ranging from 6 to about 200 oligonucleotides).
- the oligonucleotide is at least 10 nucleotides, at least 15 nucleotides, at least 100 nucleotides, or at least 200 nucleotides.
- the oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded.
- the oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone.
- the oligonucleotide may include other appending groups such as peptides, or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al, 1989, Proc. Natl. Acad. Sci. U.S.A. 86: 6553-6556; Lemaitre et al, 1987, Proc. Natl. Acad. Sci. 84: 648-652: PCT Publication No. WO 88/09810, published Dec. 15, 1988), hybridization-triggered cleavage agents (see, e.g., Krol et al, 1988, BioTechniques 6: 958-976) or intercalating agents (see, e.g., Zon, 1988, Pharm. Res. 5: 539-549).
- other appending groups such as peptides, or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al, 1989, Proc. Natl. Acad. Sci. U.S.
- an antisense oligonucleotide is provided, preferably as single-stranded DNA.
- the oligonucleotide may be modified at any position on its structure with constituents generally known in the art.
- the antisense oligonucleotides may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5- iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5- carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1- methylguanine, 1-mefhylinosine, 2,2-dimethylguanine, 2-methyladenine
- the oligonucleotide comprises at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.
- the oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.
- the oligonucleotide is a 2-cc-anomeric oligonucleotide.
- An ⁇ -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual /3-units, the strands run parallel to each other (Gautier et al, 1987, Nucl. Acids Res. 15:6625-6641).
- the oligonucleotide may be conjugated to another molecule, e.g, a peptide, hybridization triggered cross-linking agent transport agent, hybridization-triggered cleavage agent, etc.
- An antisense molecule can be a "peptide nucleic acid” (PNA).
- PNA refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition.
- PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.
- the antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of a target RNA species. However, absolute complementarity, although preferred, is not required.
- a sequence "complementary to at least a portion of an RNA,” as refe ⁇ ed to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed.
- the ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with a target RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex. The amount of antisense nucleic acid that will be effective in the inhibiting translation of the target RNA can be determined by standard assay techniques.
- the synthesized antisense oligonucleotides can then be administered to a cell in a controlled manner.
- the antisense oligonucleotides can be placed in the growth environment of the cell at controlled levels where they may be taken up by the cell.
- the uptake of the antisense oligonucleotides can be assisted by use of methods well known in the art.
- the antisense nucleic acids of the invention are controllably expressed intracellularly by transcription from an exogenous sequence.
- a vector can be introduced in vivo such that it is taken up by a cell, within which cell the vector or a portion thereof is transcribed, producing an antisense nucleic acid (RNA) of the invention.
- RNA antisense nucleic acid
- Such a vector would contain a sequence encoding the antisense nucleic acid.
- Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA.
- Such vectors can be constructed by recombinant DNA technology methods standard in the art.
- Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells.
- Expression of the sequences encoding the antisense RNAs can be by any promoter known in the art to act in a cell of interest.
- promoters can be inducible or constitutive.
- promoters are controllable or inducible by the administration of an exogenous moiety in order to achieve controlled expression of the antisense oligonucleotide.
- controllable promoters include the Tet promoter.
- promoters for mammalian cells include, but are not limited to: the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290: 304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al, 1980, Cell 22: 787-797), the he ⁇ es thymidine kinase promoter (Wagner et al, 1981, Proc. Natl. Acad. Sci. U.S.A. 78: 1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al, 1982, Nature 296: 39-42), etc.
- Antisense therapy for a variety of cancers is in clinical phase and has been discussed extensively in the literature. Reed reviewed antisense therapy directed at the Bcl-2 gene in tumors; gene transfer-mediated overexpression of Bcl-2 in tumor cell lines conferred resistance to many types of cancer drugs. (Reed, J.C, N.C.I. (1997) 59:988-990). The potential for clinical development of antisense inhibitors of ras is discussed by Cowsert,
- the level of a particular mRNA or polypeptide in a cell is reduced by introduction of a ribozyme into the cell or nucleic acid encoding such.
- Ribozyme molecules designed to catalytically cleave mRNA transcripts can also be introduced into, or expressed, in cells to inhibit expression of a gene (see, e.g., Sarver et al., 1990, Science 247: 1222-1225 and U.S. Patent No. 5,093,246).
- One commonly used ribozyme motif is the hammerhead, for which the substrate sequence requirements are minimal. Design of the hammerhead ribozyme is disclosed in Usman et al, Current Opin. Struct. Biol.
- Ribozymes can also be prepared and used as described in Long et al, FASEB J. (1993) 7:25; Symons, ⁇ « «. Rev. Biochem. (1992) 67:641; Perrotta et al, Biochem. (1992) 37:16- 17; Ojwang et al, Proc. Natl. Acad. Sci. (USA) (1992) 89: 10802-10806; and U.S. Patent No. 5,254,678. Ribozyme cleavage of HIV-I RNA is described in U.S. Patent No.
- RNA interference is the process of sequence-specific, post- transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene.
- dsRNA double-stranded RNA
- long dsRNA are cleaved by ribonuclease III to generate 21- and 22-nucleotide siRNAs.
- 21 -nucleotide siRNA duplexes specifically suppress expression of endogenous and heterologous genes in different mammalian cell lines, including human embryonic kidney (293) and HeLa cells (Elbashir et al. Nature 2001 ;411(6836):494-8). Accordingly, translation of a gene in a cell can be inhibited by contacting the cell with short doublestranded RNAs having a length of about 15 to 30 nucleotides, preferably of about 18
- a vector encoding for such siRNAs or hai ⁇ in RNAs that are metabolized into siRNAs can be introduced into a target cell (see, e.g, McManus et al. (2002) RNA 8:842; Xia et al. (2002) Nature Biotechnology 20:1006; and Brummelkamp et al. (2002) Science 296:550.
- Vectors that can be used are commercially available, e.g, from OligoEngine under the name pSuper RNAi SystemTM.
- Gene expression can also be reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of the target gene (i.e., the gene promoter and/or enhancers) to form triple helical structures that prevent transcription of the gene in target cells in the body.
- deoxyribonucleotide sequences complementary to the regulatory region of the target gene i.e., the gene promoter and/or enhancers
- triple helical structures that prevent transcription of the gene in target cells in the body.
- RNA aptamers can be introduced into or expressed in a cell.
- RNA aptamers are specific RNA ligands for proteins, such as for Tat and Rev RNA (Good et al, 1997, Gene Therapy 4: 45-54) that can specifically inhibit their translation.
- Yet another method of decreasing the biological activity of a polypeptide is by introducing into the cell a dominant negative mutant. A dominant negative mutant polypeptide will interact with a molecule with which the polypeptide normally interacts, thereby competing for the molecule, but since it is biologically inactive, it will inhibit the biological activity of the polypeptide.
- a dominant negative mutant of a protein can be created, e.g, by mutating the substrate-binding domain, the catalytic domain, or a cellular localization domain of the polypeptide.
- the mutant polypeptide will be ove ⁇ roduced. Point mutations are made that have such an effect.
- fusion of different polypeptides of various lengths to the terminus of a protein can yield dominant negative mutants. General strategies are available for making dominant negative mutants. See Herskowitz, Nature (1987) 529:219-222.
- the activity of one or more proteins selected from the group consisting of NPTl, PNCl, NMAl and NMA2 is decreased. This can be accomplished, e.g, by contacting a cell with a compound that inhibits the activity, e.g, enzymatic activity, of one of these proteins. Assays for identifying such compounds are further described herein.
- the flux through the NAD+ salvage pathway in a cell is decreased by contacting the cell with nicotinamide or a variant thereof having substantially
- a cell is contacted with an amount of nicotinamide of about 0.1 mM to about 100 mM, preferably about 1 mM to about 20mM, even more preferably 2 mM to about 10 mM, and most preferably about 5 mM. Nicotinamide is commercially available (see, e.g, the source provided in the Examples).
- a cell is contacted with nicotinamide for a time sufficient to exert the desired effect. For example, a cell can be contacted for at least about 60 minutes or at least about 24 hours with nicotinamide. A cell may also be contacted continously with nicotinamide.
- nicotinamide In addition to nicotinamide, cells can be contacted with analogs thereof.
- exemplary analogs include Pyrazinamide, which is sold as an antituberculous agent.
- Analogs can be identified, e.g, by screening of combinatorial libraries of analogs for those having the desired activity. For example, an assay for measuring life span can be used.
- analogs of nicotinamide or agents that interact with the C pocket of Sir2 family members can be identified by rational drug design, as further described herein.
- nicotinamide examples include compounds of formula I:
- L is O, NR, or S;
- R is alkyl or phenyl;
- R ! is -NH 2 , -O-alkyl, -N(R) 2 , or -NH(R);
- Het is heteroaryl or heterocycloalkyl.
- Particular analogs that may be used include compounds of formula I and the attendant definitions, wherein L is O; compounds of formula I and the attendant definitions, wherein Ri is -NH 2 ; compounds of formula I and the attendant definitions, wherein Het is selected from the group consisting of pyridine, furan, oxazole, imidazole, thiazole, isoxazole, pyrazole, isothiazole, pyridazine, pyrimidine, pyrazine, pyrrole, tetrahydrofuran, 1 :4 dioxane, 1,3,5-trioxane, pyrrolidine, piperidine, and piperazine; compounds of formula I and the attendant definitions, wherein Het is pyridine; compounds of formula I and the attendant definitions, wherein L is O and R, is -NH 2 ; compounds of formula I and the attendant definitions, wherein L is O and Het is pyridine; compounds of formula I and the attendant definitions, wherein Ri is
- L is O, NR, or S;
- R is alkyl or phenyl;
- R is -NH 2 , -O-alkyl, -N(R) 2 , or -NH(R);
- X is H, alkyl, -O-alkyl, OH, halide, or NH 2 ; and
- n is an integer from 1 to 4 inclusive.
- Particular analogs that may be used include compounds of formula II and the attendant definitions, wherein L is O; compounds of formula II and the attendant definitions, wherein Ri is -NH 2 ; compounds of formula II and the attendant definitions, wherein X is H and n is 4; compounds of formula II and the attendant definitions, wherein L is O and R ⁇ is -NH 2 ; compounds of formula II and the attendant definitions, wherein L is O, X is H, and n is 4; compounds of formula II and the attendant definitions, wherein R ⁇ is - NH 2 , X is H, and n is 4; and compounds of formula II and the attendant definitions, wherein L is O, Ri is -NH 2 , X is H, and n is 4.
- any inhibitor of a Sir2 family member can be used to reduce the life span of cells.
- Preferred inhibitors are molecules that bind to the C pocket of a Sir2 family member, e.g, nicotinamide or analogs thereof.
- the level or activity of enzymes that produce nicotinamide can be increased in a cell in which it is desired to reduce its lifespan or render it more susceptible to stress.
- the level or activity of enzymes involved in the biosynthesis of nicotinamide in the NAD+ salvage pathway or in de novo synthesis pathways can be increased. Exemplary enzymes are set forth above in the previous section.
- Yet another method for increasing the level of nicotinamide in cells includes inhibiting enzymes that inactivate or degrade nicotinamide, e.g, nicotinamide methyl transferase in yeast and human cells; nicotinamide phosphoribosyltransferase in human cells (discussed above) and yeast NPTl or human homologs thereof (also described above).
- enzymes that inactivate or degrade nicotinamide e.g, nicotinamide methyl transferase in yeast and human cells; nicotinamide phosphoribosyltransferase in human cells (discussed above) and yeast NPTl or human homologs thereof (also described above).
- nicotinamide levels can be increased in cells by increasing the level or activity of glycohydrolases, which cleave NAD to nicotinamide. It is also possible to increase the level or activity of nicotinamide transporters to increase the level of nicotinamide in cells.
- Agents include small molecules, e.g, small organic molecules, or any biological macromolecule, e.g, a nucleic acid, such as DNA or RNA, single stranded or double stranded; a protein or peptide; a polysaccharide; a lipid; or molecular combinations thereof.
- a method for identifying a compound that modulates the life span of a cell or its resistance to certain types of stresses comprises (i) contacting a protein selected from the group consisting of NPTl, PNCl , NMAl and NMA2 with a test compound for an amount of time that would be sufficient to affect the activity of the protein; and (ii) determining the activity of the enzyme, wherein a difference in the activity of the enzyme in the presence of the test compound relative to the absence of the test compound indicates that the test compound is a compound that modulates the life span of the cell.
- the method may further comprise contacting a cell with the test compound and determining whether the life span of the cell has been modulated.
- the method may further comprise contacting a cell with the test compound and determining whether the resistance of the cell to certain stresses, e.g, heatshock, osmotic stress, high temperature, calorie restriction, DNA damaging agents (e.g, UN. and the mitochondrial mutagen ethidium bromide), inappropriate nitrogen conditions, has been modulated. Determining the activity of the enzyme can be conducted as further described herein. It can also consist of measuring the effect of the test compounds on the life span of a cell or on its resitance to stress, e.g, heatshock, osmotic stress, etc.
- stresses e.g, heatshock, osmotic stress, high temperature, calorie restriction, DNA damaging agents (e.g, UN. and the mitochondrial mutagen ethidium bromide), inappropriate nitrogen conditions.
- Determining the activity of the enzyme can be conducted as further described herein. It can also consist of measuring the effect of the test compounds on the life span of a cell or on its resitance to stress,
- the above-assay can also be conducted with a biologically active portion or variant of one of the above-described proteins, such as those described above.
- a portion of a protein can consist of
- the catalytic site of S. cerevisae and human NPTl is located between about amino acids 209 and 240.
- the catalytic site of S. cerevisiae PNCl is located at about amino acids 150-186.
- the catalytic site of human NMNAT (homolog of NMAl and NMA2) is located at about amino acids 100-110 and 280-310 (both sequences contribute to the active site).
- the invention provides a method for identifying a compound that modulates the life span of a cell or its resistance to certain types of stresses, comprising (i) contacting a cell or a lysate, comprising a transcriptional regulatory nucleic acid of a gene selected from the group consisting of NPTl , PNCl, NMAl and NMA2 operably linked to a reporter gene, with a test compound for an amount of time that would be sufficient to affect the transcriptional regulatory nucleic acid; and (ii) determining the level or activity of the reporter gene, wherein a difference in the level or activity of the reporter gene in the presence of the test compound relative to the absence of the test compound indicates that the test compound is a compound that modulates the life span of the cell or its resistance to certain types of stresses.
- the method may further comprise contacting a cell with the test compound and determining whether the life span of the cell has been modulated.
- the method may also further comprise contacting a cell with the test compound and determining whether the resistance of the cell to certain stresses, e.g, heatshock, has been modulated.
- Transcriptional regulatory nucleic acids are either known in the art or can easily be isolated according to methods well known in the art.
- the reporter gene can be any gene encoding a protein whose expression can be detected, e.g, by fluorescence activated cell sorting.
- the cell can be a prokaryotic or eukaryotic cell.
- the lysate can be a complete lysate of a cell, prepared according to methods known in the art, or it can be a fraction of a cell lysate or a combination of several cell lysates or fractions of cell lysates.
- a lysate may also comprise one or more recombinant proteins.
- the invention also provides methods for regulating the level of nicotinamide in cells. Such methods may comprising identifying agents that modulate an enzyme that increases or decreases nicotinamide levels in a cell. Exemplary enzymes are described herein. Assays can be conducted essentially as described above for identifying agents that modulate the NAD+ salvage pathway.
- nicotinamide inhibits Sir2 and human SRT1. It has also been shown that nicotinamide inhibits Sir2 non-competitively by binding to the C pocket of
- the invention provides assays, e.g, based on rational drug design, for identifying analogs of nicotinamide that are also inhibitors of Sir2 and other members of the Sir2 family of proteins which comprise a C pocket.
- the present invention provides methods of identifying agents that can be used for reducing the life span of cells, such as to treat conditions that may benefit from reducing the life span of certain cells.
- One such embodiment comprises a method of identifying an agent for use as an inhibitor of a Sir2 family member using a dataset comprising the three-dimensional coordinates of at least a portion a Sir2 family member comprising the C pocket.
- the crystal structure of a Sir2 homolog is described in Min et al. (2001 ) Cell 105 269 and the structure is provided in Protein Data Bank ID code 1 ICI.
- the C pocket is located at about amino acids 70-90 and 127-167 of human SIRTl .
- the C pocket of Sir2 is located at about amino acids 250-270 and 310-350.
- the coordinates may further comprise the coordinates of nicotinamide or an analog thereof.
- the three-dimensional coordinates are those of a Sir2 homolog.
- assays comprise co-crystallizing at least a portion of a Sir2 family member comprising the C pocket with a compound, e.g, a nicotinamide analog. Co-crystallization may be in the presence or absence of NAD+.
- a potential agent is selected by performing rational drug design with the three-dimensional coordinates of a portion of a Sir2 family member comprising at least the C pocket. As noted above, preferably the selection is performed in conjunction with computer modeling. The potential agent is then contacted with the Sir2 family member and the activity of the Sir2 family member is determined (e.g., measured). A potential agent is identified as an agent that inhibits a Sir2 family member when there is a decrease in the activity determined for the Sir2 family member. In a preferred embodiment the method further comprises preparing a supplemental crystal containing at least a portion of a Sir2 family member comprising the C pocket bound to the potential agent.
- the supplemental crystal effectively diffracts X- rays for the determination of the atomic coordinates to a resolution of better than 5.0 Angstroms, more preferably to a resolution equal to or better than 3.5 Angstroms, and even more preferably to a resolution equal to or better than 3.3 Angstroms.
- the three-dimensional coordinates of the supplemental crystal are then determined with molecular replacement analysis and a second generation agent is selected by performing rational drug design with the three-dimensional coordinates determined for the
- the second generation agent can be an analog of nicotinamide.
- the three-dimensional structure of a supplemental crystal can be determined by molecular replacement analysis or multiwavelengfh anomalous dispersion or multiple isomo ⁇ hous replacement.
- a candidate drug can then selected by performing rational drug design with the three-dimensional structure determined for the supplemental crystal, preferably in conjunction with computer modeling.
- the candidate drug can then be tested in a large number of drug screening assays using standard biochemical methodology exemplified herein.
- the method can further comprise contacting the second generation agent with a Sir2 family member or portion thereof of a different species and determining (e.g., measuring) the activity of the Sir2 family member or portion thereof of the other species.
- a potential agent is then identified as an agent for use as an essentially specific inhibitor of a Sir2 family member of a first species when there is significantly less change (a factor of two or more) in the activity of the Sir2 family member of other species relative to that observed for the Sir2 family member of the first species. Preferably no, or alternatively minimal change (i.e., less than 15%) in the activity of the other species is observed.
- the present invention provides a computer-assisted method for identifying an inhibitor of the activity of a Sir2 family member including: supplying a computer modeling application with a set of structure coordinates of a molecule or molecular complex, the molecule or molecular complex including at least a portion of a Sir2 family member comprising a C pocket; supplying the computer modeling application with a set of structure coordinates of a chemical entity, e.g, an analog of nicotinamide; and determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex, wherein binding to or interfering with the molecule or molecular complex is indicative of potential inhibition of the activity of the Sir2 family member.
- a chemical entity e.g, an analog of nicotinamide
- Preferably determining whether the chemical entity is an inhibitor expected to bind to or interfere with the molecule or molecular complex includes performing a fitting operation between the chemical entity and a binding pocket of the molecule or molecular complex, followed by computationally analyzing the results of the fitting operation to quantify the association between the chemical entity and the binding pocket.
- the method may further includes screening a library of chemical entities.
- the method may also further include supplying or synthesizing the potential inhibitor, then assaying the potential
- the present invention provides a method for making an inhibitor of a Sir2 family member, the method including chemically or enzymatically synthesizing a chemical entity to yield an inhibitor of the activity of a Sir2 family member, the chemical entity having been designed during a computer-assisted process, e.g, as described above.
- the present invention further provides an apparatus that comprises a representation of a complex between Sir2 family member and nicotinamide or analog thereof.
- One such apparatus is a computer that comprises the representation of the complex in computer memory.
- the computer comprises a machine-readable data storage medium which contains data storage material that is encoded with machine-readable data which comprises the atomic coordinates of the complex.
- the computer may further comprise a working memory for storing instructions for processing the machine-readable data, a central processing unit coupled to both the working memory and to the machine- readable data storage medium for processing the machine readable data into a three- dimensional representation of the complex.
- the computer also comprises a display that is coupled to the central-processing unit for displaying the three- dimensional representation. 6.
- increasing the flux through the NAD+ salvage pathway or decreasing nicotinamide levels is used to increase the life span of cells and protect cells against at least certain stresses in vitro.
- cells in culture can be treated as described herein, such as to keep them proliferating longer. This is particularly useful for primary cell cultures (i.e., cells obtained from an organism, e.g, a human), which are known to have only a limited life span in culture.
- Treating such cells according to methods of the invention e.g, by integrating one or more additional copies of one or more genes selected from the group consisting of NPTl, PNCl, NMAl, NMA2, nicotinamide N-methyl transferase (NNMT and NNT1), nicotinamide phosphoribosyltransferase (NAMPRT), and optionally human nicotinamide mononucleotide adenylyltransferase (NMNAT, NMAT-1 and 2), will result in increasing the amount of time that the cells are kept alive in culture.
- NPTl e.g, by integrating one or more additional copies of one or more genes selected from the group consisting of NPTl, PNCl, NMAl, NMA2, nicotinamide N-methyl transferase (NNMT and NNT1), nicotinamide phosphoribosyltransferase (NAMPRT), and optionally human nicotinamide mononucleot
- Embryonic stem (ES) cells and pluripotent cells, and cells differentiated therefrom can also be modified according to the methods of the invention such as to keep the cells or progeny thereof in culture for longer periods of time.
- Primary cultures of cells, ES cells, pluripotent cells and progeny thereof can be used, e.g, to
- cells that are intended to be preserved for long periods of time are treated as described herein.
- the cells can be cells in suspension, e.g, blood cells, or tissues or organs.
- blood collected from an individual for administering to an individual can be treated according to the invention, such as to preserve the blood cells for longer periods of time.
- Other cells that one may treat for extending their lifespan and/or protect them against certain types of stresses include cells for consumption, e.g, cells from non-human mammals (such as meat), or plant cells (such as vegetables).
- cells obtained from a subject e.g, a human or other mammal, are treated according to the methods of the invention and then administered to the same or a different subject.
- cells or tissues obtained from a donor for use as a graft can be treated as described herein prior to administering to the recipient of the graft.
- bone marrow cells can be obtained from a subject, treated ex vivo to extend their life span and protect the cells against certain types of stresses and then administered to a recipient.
- the cells of the graft e.g, bone marrow
- the graft can be an organ, a tissue or loose cells.
- cells are treated in vivo to increase their life span and/or protect them against certain types of stresses.
- skin can be protected from aging, e.g, developing wrinkles, by treating skin, e.g, epithelial cells, as described herein.
- skin is contacted with a pharmaceutical or cosmetic composition comprising a compound that is capable of increasing the transcription of one or more genes selected from the group consisting of NPTl, PNCl, NMAl, NMA2,
- skin cells are contacted with a composition comprising a protein selected from the group consisting of NPTl, PNCl, NMAl , NMA2, NMNAT, NNT1, NAMPRT, and optionally NMAT-1 or 2, or a nucleic acid encoding such, and a vehicle for delivering the nucleic acid or protein to the cells.
- a composition comprising a protein selected from the group consisting of NPTl, PNCl, NMAl , NMA2, NMNAT, NNT1, NAMPRT, and optionally NMAT-1 or 2, or a nucleic acid encoding such, and a vehicle for delivering the nucleic acid or protein to the cells.
- nucleic acids and proteins can also be delivered to a tissue or organ within a subject, such as by injection, to extend the life span of the cells or protect the cells against certain stresses.
- an agent of the invention is administered to subjects, such as to generally increase the life span of its cells and protect its cells against certain types of stresses.
- an agent can be taken by subjects as food supplements.
- such an agent is a component of a multi-vitamin complex.
- Agents that extend the life span of cells and protect them from stress can also be administered to subjects for treatement of diseases, e.g, chronic diseases, associated with cell death, such as to protect the cells from cell death, e.g, diseases associated with neural cell death or muscular cell death.
- diseases include Parkinson's disease, Alzheimer's disease, multiple sclerosis, amniotropic lateral sclerosis, and muscular dystrophy.
- the agent may be administered in the tissue or organ likely to encounter cell death.
- Such agents can also be administered to a subject suffering from an acute damage to an organ or tissue, e.g, a subject suffering from stroke or myocardial infarction or a subject suffering from a spinal cord injury. Agents can also be used to repair an alcoholic's liver.
- DNA repair is also inhibited by nicotinamide
- agents that reduce nicotinamide levels in cells can be used to promote DNA repair in cells. Accordingly, cells exposed to conditions that may trigger DNA damage, e.g, U.S. radiation and ethidium bromide, may be protected by contacting them before, during and/or after exposure to the DNA damaging agent, with an agent that reduces nicotinamide levels in the cell.
- the methods of the invention are applied to yeast cells.
- Situations in which it may be desirable to extend the life span of yeast cells and to protect them against certain types of stress include any process in which yeast is used, e.g, the making of beer, yogurt, and bakery, e.g, making of bread.
- Use of yeast having an extended life span can result in using less yeast or in having the yeast be active for longer periods of time.
- the invention also provides methods for reducing the life span of a cell or rendering it more susceptible to certain stresses, e.g, heatshock, radioactivity, osmotic stress, DNA damage, e.g, from UN. Such methods can be used whenever it is desired to reduce the life span of a cell. Exemplary methods include decreasing the level or activity of a protein selected from the group consisting of ⁇ PT1, P ⁇ C1, ⁇ MA1, ⁇ MA2, NMNAT, NNT1, NAMPRT, and optionally NMAT-1 or 2.
- Another method includes increasing the level of nicotinamide in the cell, e.g, by contacting the cell with nicotinamide, or by increasing the level or activity of an enzyme stimulating nicotinamide biosynthesis or decreasing the level or activity of an enzyme inhibiting or degrading nicotinamide, e.g, by decreasing the level or activity of NPTl, PNCl, NMAl, NMA2, NMNAT, NNT1, NAMPRT, and optionally NMAT-1 or 2.
- Exemplary situations in which one may wish to reduce the life span of a cell or render it more susceptible to certain stresses include treatment of cancer, autoimmune diseases or any other situation in which it is desirable to eliminate cells in a subject.
- Nicotinamide or other compounds or agents of the invention can be administered directly to the area containing the underirable cells, e.g, in a tumor. These methods can also be used to eliminate cells or prevent further proliferation of undesirable cells of non-malignant tumors, e.g, warts, beauty spots and fibromas.
- nicotinamide can be injected into a wart, or alternatively be included in a pharmaceutical composition for applying onto the wart.
- Methods for decreasing the life span of cells or increasing their susceptibility to certain stresses can be applied to yeast, e.g, yeast infecting subjects. Accordingly, a composition comprising an agent, e.g, nicotinamide, can be applied to the location of the yeast infection.
- an agent e.g, nicotinamide
- Subjects that may be treated as described herein include eukaryotes, such as mammals, e.g, humans, ovines, bovines, equines, porcines, canines, felines, non-human primate, mice, and rats.
- Cells that may be treated include eukaryotic cells, e.g, from a subject described above, or plant cells, yeast cells and prokaryotic cells, e.g, bacterial cells. 7.
- Pharmaceutical compositions and methods Compounds, nucleic acids, proteins, cells and other compositions can be administered to a subject according to methods known in the art. For example, nucleic acids encoding a protein or an antisense molecule can be administered to a subject as described above, e.g, using a viral vector.
- Cells can be administered according to methods for administering a graft to a subject, which may be accompanied, e.g, by administration of an immunosuppressant drug, e.g, cyclosporin A.
- an immunosuppressant drug e.g, cyclosporin A.
- the reader is referred to Cell Therapy: Stem Cell Transplantation, Gene Therapy, and Cellular Immunofherapy, by G. Morstyn & W. Sheridan eds, Cambridge
- Example 1 Manipulation of a nuclear NAD + salvage pathway delays aging
- NPTl NAD + -dependent histone deacetylase
- W303cdc25-10 W303 MATa, ⁇ de2-l, leu2-3, 112, c ⁇ nl-100, trpl-1, ur ⁇ 3-52, h ⁇ s3-ll,lS, RDNl ADE2, RADS, cdc25-10
- NPTl Additional copies of NPTl were integrated at the URA3 locus using plasmid pSPNPTl linearized with Stnl. Integrants were first identified by PCR. NP77 copy- number was then determined by probing for N 77 and ACTl D ⁇ A on Southern blots. The density of the NP77 band was compared to an ACTl band using ImageQuant software (Molecular Dynamics, Sunnyvale, CA). Strains carrying an additional copy of SIR2 were generated by integrating plasmids p306SIR2 or p305SIR2 (17) linearized with Xcml. High
- 61 - copy SIR2 was introduced on the 2 ⁇ -based plasmid p2 ⁇ SIR2 (gift of L. Pillus, UCSD).
- W303AR5 was transformed to Ura + and Leu + prototrophy by integrating pRS306 or pRS305 (45) linearized with Stul and Xcml respectively.
- YDS 1595 was generated from W303AR5 by selecting a colony that had experienced an ADE2 loss event.
- YDS 1595 was transformed with Stwl-cut pRS402 (carrying the ADE2 gene) to create YDS 1596.
- W303cdc25-10 was a gift from S. Lin (M.I.T) (19).
- the NP77 deletion strain, YDS1580, was generated by replacing the wildtype gene with the k ⁇ n r marker as described (46).
- the coding region and 650 bp upstream of PNCl /YGL037 was amplified by PCR from genomic D ⁇ A.
- the 1350 bp S ⁇ cl/Notl fragment was cloned into the vector pSR400 to generate pSPYGL037.
- the coding region and 500 bp upstream of NMA2IYGR010 were amplified by PCR from genomic template and the 1730 bp S ⁇ cl/Notl fragment was cloned into pSP400 to generate pSPYGROlO.
- the coding region of NMA1/YLR328 and 450 bp upstream were amplified from genomic template by PCR and the 2150 bp fragment was cloned into pRS306 to generate p306YLR328.
- the coding region and 600 bp upstream of QNS1/YHR074 was amplified by PCR and the 2.8 kb S ⁇ cIINotI fragment was cloned into pSP400 to make pSPYHR074.
- W303AR5 and W303cdc25-10 (19).
- a green fluorescent protein (GFP) cassette was introduced at the carboxy-terminus of ⁇ ptl, ⁇ mal and ⁇ ma2 as described (48). The functionality of tagged proteins was confirmed by assaying rDNA silencing.
- GFP green fluorescent protein
- Life span determination Replicative life span determination was performed as described (16). Cells were grown on YPD medium (1% yeast extract, 2% bactopeptone, 2% glucose w/v) unless otherwise stated with a minimum of 40 cells per experiment. Each experiment was performed at least twice independently. Statistical significance of life span differences was determined using the Wilcoxon rank sum test. Differences are stated to be different when the confidence is higher than 95%.
- mRNA and protein determination Northern and Western blots were performed using standard techniques. NPTl transcripts were detected using a probe derived from the complete open reading frame of the NPTl gene. ACTl mRNA was detected using a full- length ACTl probe (gift of G. Fink, M.I.T). The HA epitope tag was detected using
- Yeast assays and GFP localization were grown at 30°C unless otherwise stated.
- the extent of silencing at the ribosomal DNA locus was determined using two assays.
- SC synthetic complete
- cells were pre-grown on synthetic complete (SC) medium (1.67% yeast nitrogen base, 2%> glucose, 40 mg/1 of histidine, uridine, tryptophan, adenine and leucine) for 3 days.
- Cells were resuspended in SD medium and serially diluted 10-fold in phosphate-buffered saline and spotted onto SC medium lacking adenine.
- METIS silencing assays were performed on Pb 2+ -containing plates as previously described (42).
- Telomeric silencing was assayed on SC medium containing 0.7 mg/1 adenine. Cells were grown for 3 days and placed at 4°C for 3 days to enhance color. Heat shock assays were performed essentially as described (14). Strains were pre-grown overnight in SC-complete medium with limiting histidine (20 mg/ml), diluted to 1x10 s cells/ml in 3 ml of the same medium and grown for 5 days. Cultures were diluted 10-fold in expired medium, incubated for 1 h at 55°C and spotted on SC plates. Ribosomal DNA recombination rates were determined as previously described (49). At least 10,000 colonies were examined for each strain and each experiment was performed in triplicate.
- NAD + and NADH determinations were measured as described elsewhere (50).
- Cells expressing a GFP fusions were grown to mid log phase in YPD medium or YPD low glucose (0.5%) w/v) then incubated in PBS containing 20 ⁇ M Hoechst 33342 DNA stain (Sigma) for 5 min. Images were captured under a 100X magnification on a Nikon E600 fluorescence microscope and analyzed using Photoshop 6.0 software. RESULTS Increased dosage of NPTl increases longevity but not steady-state NAD + levels — SIR2 is a limiting component of longevity in yeast and requires NAD + for catalysis. Studies in E.
- coli have shown that PncB catalyzes a rate-limiting step in the salvage pathway that recycles NAD + (35,37,38).
- NPTl pncB homolog
- NR77 was integrated at the URA3 locus under the control of its native promoter. Strains that carried one or four tandem copies of NPTl were then identified by Southern blotting. We refer to the resulting genotypes as 2xNPTl and 5xNPTl respectively.
- Genotype (amol/pg (amol/pg ratio (amol/pg protein) 1 protein) 1 protein) 1
- MMS methylmethane sulfonate
- strains with an additional copy of NPTl or SIR2 were grown to stationary phase in SC medium, heat shocked for 1 hour at 55°C, then spotted in 10-fold serial dilutions onto SC plates.
- stains with a single additional copy of NPTl or SIR2 were significantly more resistant to heat shock than the otherwise isogenic wild type control strain. No additive effect of NPTl and SIR2 was apparent, consistent with these two genes acting in the same pathway.
- strains were subjected to 1 hour heat shock, plated for single colonies and the number of colonies after 24 hours was scored as a percentage of the untreated sample.
- additional copies of NPTl and SIR2, or both provided -8-fold greater survival than wild type, consistent with our earlier finding.
- sir4 mutants relocalize Sir2 to the rD ⁇ A, which may counteract the high levels of ⁇ ptl .
- Additional copies of NPTl in a sir2 mutant caused a slight increase in rD ⁇ A silencing that was considerably weaker than SIR2- dependent silencing. The basis of this apparent increase is unclear.
- silencing at a telomeric locus An additional copy of NPTl was introduced into PSY316AT, which has an ADE2 marker inserted in the subtelomeric region of chromosome V (53). As shown in Fig.
- Caloric restriction does not alter NPTl expression or localization — Given that additional NPTl and caloric restriction appear to extend life span via the same pathway, we tested whether caloric restriction acts by increasing NP77 expression.
- a triple hemagglutinin epitope (3xHA) tag was added to the carboxy-terminus of ⁇ ptl by integrating an 3xHA-kanamycin resistance cassette into the native NPTl locus.
- the fusion protein was functional by assaying its ability to maintain wild type levels of rD ⁇ A silencing. NPTl levels were then determined in strains grown on (0.5%) glucose medium and in the long-lived cdc25-10 strain, which is considered a genetic mimic of caloric restriction (19). As shown in Fig.
- NAD + salvage pathway exists in the nuclear compartment, then we should expect that the other enzymes in the pathway will show a similar localization pattern to Nptl .
- the step immediately downstream of NPTl is predicted to be catalyzed by a nicotinate mononucleotide adenylyltransferase (NaMAT).
- NaMAT nicotinate mononucleotide adenylyltransferase
- yeast ORFs with similar homology to NaMATs from other species YLR0328 and YGR010, which we have designated NMAl and NMA2, respectively.
- a GFP cassette was integrated in frame prior to the stop codon of each ORF to generate C-terminal fusions. As shown in Fig.
- Nma2-GFP was concentrated in the nucleus in the majority of cells, in a pattern identical to that of Nptl-GFP. This finding further supports our hypothesis that NAD + is recycled from nicotinamide entirely within the nucleus. The localization pattern of Nmal was unable to be determined due to low expression levels. Identification of other putative longevity genes in the NAD + salvage pathway — The discovery that Nma2 shows a similar localization to Nptl prompted us to test whether other genes in the NAD + salvage pathway could have similar effects to Nptl when overexpressed. While the bacterial genes in NAD salvage pathway have been studied in detail, in S. cerevisiae some of the key genes in the pathway remain to be characterized.
- PNCl a recently identified gene, encodes a nicotinamidase which catalyses the conversion of nicoinamide to nicotinic acid, the step immediately upstream of NPTl.
- NMAl and NMA2 encode NaMNATs which catalyze the step immediately downstream of NPTl.
- NAD + an uncharacterized ORF, QNS1IYHR074, shows high homolgy to NAD synthetases.
- Each of these salvage pathway genes was integrated as a single copy into the URA3 locus of W303AR5 and PSY316AT and assayed for silencing as previously described. Additional copies of either PNCl, NMAl or NMA2 increased rDNA and telomeric silencing to levels similar to those in a IxNPTl strain (Fig. 5B and C). In contrast, additional copies of QNS1 had no effect on either rDNA silencing (Fig. 5B) or telomeric silencing. As discussed below, these results indicate there are multiple steps that can affect the rate of the pathway and that the two homologs NMAl and NMA2 may have overlapping functions.
- NPTl encodes a key component of the yeast salvage pathway that recycles NAD + , a cofactor of Sir2.
- additional copies of NPTl increase life span by up to 60% in a S7R2-dependent manner. It has been proposed that longevity in yeast may be associated with increased NAD + levels.
- steady-state NAD + levels are unaltered.
- the NAD + NADH ratios are also similar to wild type cells, indicating that total cellular redox state is not dramatically altered either.
- sir2 mutants have wild type NAD + levels, implying that Sir2 is not a major consumer of NAD + . Nevertheless, by virtue of its ability to convert NAD + to nicotinamide, Sir2 should be responsive to increased flux through the salvage pathway (Fig. 6). Thus, while steady-state levels of NAD + remain constant, the turnover of this molecule may be elevated. Localization of GFP-tagged enzymes indicated that at least two of the enxymes in the NAD salvage pathway are concentrated in the nucleus. Consistent with this, Nmal and Nma2 have been shown by high-throughput 2-hybrid screening to interact with S ⁇ l, a protein that acts as a receptor for nuclear localization sequences (NLS) (54).
- NLS nuclear localization sequences
- Nmal and Nma2 can interact with themselves and with each other.
- Nma proteins exist as dimers, as is the case for the Bacillus subtilis NaMNAT (55), or as hexamers, as is the case for Methanococcus jannaschii (56) and Methanobacterium thermoautotrophicum NaMNATs (57). It is worth nothing that strains disrupted for either NMAl or NMA2 are viable (58), arguing that they are functionally redundant.
- NaMNAT/NMNAT activity is primarily observed in the nuclear fraction of liver cell extracts (59), suggesting that nuclear compartmentalization of the pathway may be a universal property of eukaryotic cells. Having the salvage pathway in proximity to chromatin may allow NAD + to be rapidly regenerated for silencing proteins. Alternatively, it may permit the coordination of a variety of nuclear activities via the alteration of nuclear NAD + pools. Testing of these hypotheses will not be a simple task but one that will be greatly assisted by the development of a molecular probe for intracellular NAD + .
- Example 2 Increased genomic instability and accelerated aging by nicotinamide
- the Saccharomyces cerevisiae Sir2 protein is an NAD + -dependent histone deacetylase that plays a critical role in transcriptional silencing, genome stability and longevity.
- a human homologue of Sir2, SIRTl regulates the activity of the p53 tumor suppressor and inhibits apoptosis.
- the Sir2 deacetylation reaction generates two products: O-acetyl-ADP-ribose and nicotinamide, a precursor of nicotinic acid and a form of niacin/vitamin B3.
- Nicotinamide completely abolishes yeast silencing and shortens replicative life span to that of a sir2 mutant. Nicotinamide, but not nicotinic acid, strongly inhibits silencing at the telomeres, rDNA and mating type loci of yeast. Nicotinamide also increases instability of the rDNA locus and shortens yeast life span to that of a sir2 mutant. Nicotinamide also abolishes silencing in GI -arrested cells,
- nicotinamide In the presence of nicotinamide, Sir2 no longer associates with either telomeres or mating type loci, but remains associated with the rDNA. Sir2 no longer co-immunoprecipitates with chromatin at telomeres and mating-type loci in the presence of nicotinamide, though the Sir2 localization pattern is unaltered.
- physiological concentrations of nicotinamide non-competitively inhibit both Sir2 and SIRTl in vitro.
- the degree of inhibition of SIRTl by nicotinamide (IC 50 ⁇ 50 ⁇ M) is equal to or better than the most effective known inhibitors of this class of proteins.
- nicotinamide and NAD + can bind simultaneously to Sir2 preventing catalysis and discuss the possibility that inhibition of Sir2 by nicotinamide is physiologically relevant.
- the extent of silencing at the ribosomal DNA locus was determined by growing RDN1::MET15 strains on Pb 2+ -containing medium (0.3%> peptone, 0.5% yeast extract, 4% glucose, 0.02% (w/v) ammonium acetate, 0.07% Pb(NO 3 ) 2 and 2% agar).
- ADE2 -based telomeric and HM locus silencing assays were performed as described previously (see, Example 1). Ribosomal DNA recombination frequencies were determined as previously described (44'). Table 3. Yeast strains used in this study.
- W303AR5 W303 MATa, ⁇ de2-l, Ieu2-3,U2, c ⁇ nl-100, trpl-1, ur ⁇ 3-52, his3-ll,15,
- Replicative life span determination was performed by micromanipulation as descnbed (25'). A minimum of 40 cells were examined per experiment and each expenment was performed at least twice independently Statistical significance of life span differences was determined using the Wilcoxon rank sum test. Differences are stated to be significant when the confidence is higher than 95%.
- GFP fluorescence was quantified by fluorescence-activated cell sorting (FACS) using a FACSCahbur flow cytometer (Becton Dickinson, CA) as descnbed (45')
- FACS fluorescence-activated cell sorting
- CA FACSCahbur flow cytometer
- 76 - was determined by FACS analysis of fixed cells stained with propidium iodide (Sigma) as described (45'). Typically 20,000 cells were analyzed per sample. Data acquisition and analysis were performed using CELLQuest software (Becton Dickenson).
- PCR reactions were carried out in a 50 ⁇ l volume using a 1/5000 or a 1/12500 dilution of input DNA from precleared whole-cell extracts and a 1/50 dilution of immunoprecipitated DNA.
- PCR parameters were as follows. For CUP1 and 5S rDNA primer pairs, 26 cycles of PCR were performed with an annealing temperature of 55°C. For Tel 0.6, Tel 1.4 and HM primer pairs 32 cycles at an annealing temperature of 50°C were used. PCR products were separated by gel electrophoresis on a 2.3% agarose gel and visualized by ethidium bromide staining. Table 4. Oligonucleotide Sequences Oligonucleotide Sequence
- nicotinamide (0, 50, 150 or 300 ⁇ M) (Sigma), or 50 ⁇ M of the following inhibitors; nicotinic acid (Sigma), sirtinol, Ml 5 (Chembridge), splitomicin (47), TSA (BIOMOL).
- Nicotinamide abolishes silencing at the rDNA, telomeres and mating type loci. Nicotinamide is a product of Sir2 deacetylation and is a key substrate in the NAD + salvage pathway. Based on our previous observation that manipulation of NAD + biosynthesis can influence Sir2 dependent activities (see, Example 1), we wished to examine what effect NAD + precursors would have on silencing. Strains with either an ADE2 or MET 15 marker integrated at the rDNA locus (RDNl) were examined. Silencing of ADE2 results in the accumulation of a red pigment on plates with limiting adenine, whereas silencing of METIS leads to production of a brown pigment on Pb + -containing medium.
- telomeric silencing To monitor telomeric silencing, we used a strain in which the ADE2 gene is integrated at the subtelomeric (Y') region of the right arm of chromosome V (22'). On plates with limiting adenine, colonies have red white sectors due to variegated expression of the ADE2 marker. In the presence of 5 mM nicotinamide colonies were white, demonstrating a complete loss of repression (Fig. 8B). We also monitored silencing of mating type genes and found that nicotinamide completely abrogated silencing at this locus as well.
- Nicotinic acid an intermediate in the NAD + salvage pathway, is structurally similar to nicotinamide (see Fig. 9B). Nicotinic acid is taken up efficiently by yeast cells and a specific transporter for this compound, Tnal, was recently identified (48',49'). In each of the above assays, we examined the effect of 5 mM nicotinic acid on Sir2 -dependent silencing and in each case found that nicotinic acid had no effect.
- Nicotinamide increases genomic instability and shortens yeast life span. We wished to determine whether the above loss of silencing was due to inhibition of Sir2 activity, in which case nicotinamide-treated cells should mimic a sir2 ⁇ strain. Yeast lacking a functional Sir2 show increased frequencies of rDNA recombination. The loss of an ADE2 marker at the rDNA locus was monitored in wild type, 2XSIR2 and sir2 strains, in the presence and absence of nicotinamide. As shown in Figure 9A, treatment of wild type and 2XSIR2 cells with nicotinamide increased the frequency of marker loss -7-fold, similar to that of a sir2 mutant.
- Nicotinamide inhibits silencing in non-dividing cells.
- the reestablishment of silent chromatin domains requires passage through S phase (50'), although the trigger does not appear to be DNA replication (51 ',52').
- S phase 50'
- the trigger does not appear to be DNA replication
- SIR3 temperature-sensitive SIR3 allele
- nicotinamide derepresses silent domains in cycling cells and attenuates replicative life span.
- FIG. 10B shows the GFP expression profiles of asynchronous cultures of sir4 and wild type strains. Deletion of SIR4 disrupts the telomeric and mating type loci SIR complexes, leading to a redistribution of Sir2 away from these sites and to the rDNA locus. Thus, the profile of the sir4 strain represents complete derepression of the HMR locus.
- Figure 10B shows that growth of wild type cells in 5 mM nicotinamide leads to complete derepression of this locus (third panel), as compared to the sir4 mutant.
- Nicotinamide is a potent non-competitive inhibitor of both yeast Sir2 and human SIRTl in vitro. Since Sir2 was neither delocalized nor down-regulated in response to nicotinamide, the most plausible explanation for our results was that this compound acted as a direct inhibitor of Sir2 deacetylase activity. To further explore this, and to gain more insight into the mechanism of desilencing induced by nicotinamide, we directly measured Sir2 activity in vitro in the presence of varying amounts of this compound. We utilized a novel class III HDAC activity assay that generates a fluorescent signal upon deacetylation of a histone substrate.
- nicotinamide could also inhibit human SIRTl in vitro.
- SIRTl Using recombinant SIRTl, we monitored deacetylation of the substrate in the presence of varying amounts of nicotinamide and NAD + . Similar to Sir2, a Lineweaver-Burk plot of the data shows that nicotinamide also inhibits SIRTl in a non-competitive manner (Fig. 13B).
- nicotinamide inhibited SIRTl with an IC 5 o ⁇ 50 ⁇ M, a value that was equal to, or lower than, that of all the other inhibitors we tested. Adding further support to our in vivo results, we showed that the structurally related compound, nicotinic acid, had no effect on the activity of SIRTl in vitro (Fig. 13C).
- nicotinamide a product of the Sir2 deacetylation reaction
- Addition of exogenous nicotinamide to yeast cells derepresses all three silent loci, increases instability at the ribosomal DNA locus and shortens yeast life span to that of a sir2 mutant.
- rDNA instability and short life span phenotypes of nicotinamide-treated cells are not augmented by a sir2 mutation indicating that these phenotypes are the consequence of Sir2 inhibtion.
- these results also indicate that rDNA instability and life span are not influenced by the other yeast Sir2 family members, the Hst proteins.
- nicotinamide strongly inhibits the deacetylase activity of both yeast Sir2 and the human homologue, SIRTl in vitro.
- the fact that nicotinamide acts non- competitively to inhibit Sir2 suggests that this compound does not compete with NAD + for binding.
- Examination of the reaction mechanism for Sir2 deacetylation and the crystal structure of an archeal Sir2 homologue provides clues as to a possible mechanism of inhibition.
- Sir2-cataVyzed deacetylation consists of two hydrolysis steps which are thought to be coupled.
- the ADP-ribose product of this reaction then returns to the B site where deacetylation of the acetyl lysine occurs.
- nicotinamide binds to and blocks the internal C site, which prevents the conformational change and subsequent cleavage of NAD + . This would explain the non-competitive nature of the mode of inhibition of this compound.
- nicotinamide levels may directly control the activity of Sir2 proteins in vivo. These fluctuations may, in turn, be regulated by enzymes involved in nicotinamide metabolism.
- the yeast PNC7 gene encodes a nicotinamidase that is situated in a key position to regulate ⁇ AD + -dependent deacetylases. By converting nicotinamide into nicotinic acid, Pncl may reduce levels of this inhibitor and stimulate the rate at which NAD + is regenerated (see Fig.7).
- PNCl is one of the most highly induced genes in
- Nicotinamide and nicotinic acid are used at high doses (up to 10 g/day) to self-treat a wide variety of conditions (41'). Both are considered forms of vitamin B3 and are often used interchangeably, however nicotinamide has become preferred in many cases due to an apparent lack of side effects.
- nicotinamide is cu ⁇ ently in trials as a therapy to prevent cancer recu ⁇ ence and insulin-dependent (type I) diabetes.
- Our results which clearly demonstrate that nicotinamide can disrupt heterochromatin, even in non-cycling cells, raise the concern that there may be deleterious consequences of long-term nicotinamide therapy in humans.
- REFERENCES 1' Courey, A. J, S.
- Knip, M. D. I Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA. (2000)
- the nicotinamide was docked in the crystal structure of Sir2 from Archaeoglobus fulgidus (Sir2-Afl) bound to NAD + (Protein Data Bank ID code IICI, Min et al. (2001).
- Fig. 14A-C were made with PYMOL (DeLano, W.L. The PyMOL Molecular Graphics System (2002) DeLano Scientific, San Carlos, CA, USA).
- Fig. 17A PNCl catalyzes an amide hydrolysis, converting nicotinamide to nicotinic acid in the NAD + salvage pathway (Fig. 17B).
- Most wild-type yeast strains have an average lifespan of 21-23 divisions, with a maximum lifespan of -40 divisions.
- a wild-type strain that was calorie restricted (0.5% glucose) or heat stressed (37°C) exhibited a longer lifespan than an untreated control (2.0%> glucose or 30°C, respectively) (Fig. 17C and D).
- the .str2--l strain had a short lifespan, consistent with previous reports 12 ' 13 , and neither calorie restriction nor heat extended lifespan in this strain (Fig. 17C and D).
- the pncl ⁇ strain did not exhibit a lifespan extension under either of these conditions, demonstrating that RNC7 is necessary for lifespan extension.
- RNC7 is the first yeast longevity gene whose expression is modulated by stimuli that extend lifespan.
- the peroxisomal localisation is of particular interest because these organelles are a major source of reactive oxygen species and have been implicated in mammalian aging 28 ' 29 .
- a number of crucial steps in lipid metabolism occur in peroxisomes and lipid signaling has recently been linked to salt tolerance 26 .
- the salt resistance of additional PNCl maybe the result of a peroxisomal function of Pncl.
- Example 8 Life span and stress resistance are negatively regulated by intracellular nicotinamide
- a common indicator of Sir2 activity is the extent to which a reporter gene inserted at the rDNA (RDNl) is silenced.
- RDNl reporter gene inserted at the rDNA
- NAD + levels were responsible for any silencing effect
- the major route of nicotinamide metabolism is through nicotinamide N-methlytransferase (NNMT) 30 .
- NNMT nicotinamide N-methlytransferase
- NNMT converts nicotinamide to N'-methylnicotinamide, which is excreted via the kidneys 31 .
- S. cerevisiae NNMT gene which we have named NNTl.
- Nntl is 23%> identical to a mammalian NNMT core domain 30 and contains the four signature motifs of S-adenosylmethionine(SAM)-dependent methyltranferases 32 . Deletion of NNTl caused a desilencing phenotype similar to deletion of PNCl
- PNCl as a calorie restriction- and stress-responsive gene that increases lifespan and stress resistance of cells by depleting intracellular nicotinamide (Figure 21B).
- lifespan extension by calorie restriction is the result of an active cellular defense response coordinated by a specific regulatory gene.
- An attractive feature of this mechanism is that it is not based on the modulation of ⁇ AD + , an essential co- factor involved in cellular homeostasis.
- PARP Poly(adenosine diphosphate-ribose) polymerase- 1
- PARP enzymes have been implicated in numerous cellular functions including DNA break repair, telomere-length regulation, histone modification, and the regulation at the transcriptional level of key proteins including ICAM-1 and nitric oxide synthase 36 .
- the RFP-PTS1 plasmid (pSG421) was a gift from S.J. Gould (Johns Hopkins U.).
- PSY316AT-derived strains were used for lifespan analysis and stress resistance assays.
- Strains derived from PSY316AT (MATa, ura3-53 leu2-3,112 his3- ⁇ 200 ade2-l,01 canl-100 ADE2-TEL V-R): pncl ⁇ (YDS1741), sir2 ⁇ (YDS1750), SxPNCl (YDS 1853), 5xPNCl sir2 ⁇ (YOS ⁇ %5 ⁇ ),pncl ⁇ sir2 ⁇ (YDS 1853).
- W303-derived strains were used for Western blot analysis, fluorescence microscopy and SIR2 dependent silencing assays.
- Strains derived from W303 include: PNC1-GFP (YDS1742), pncl ⁇ (YDS1911), nntl ⁇ (YDS1747), 2xPNCl (YDS1588), 2xNNTl (YDS1926), ADE2 (YDS1596).
- the following strains were derived from PNC1-GFP (YDS1742): bn ⁇ 6 ⁇ (YDS1857), pSG421 (YDS1916),/?ex.5--t (YDS1869),/->ex5--1 (YDS1870) and/?ex7--1 (YDS1871).
- the cdc25-10 strain was a gift from L Guarente (M.I.T.).
- Yeast assays were conducted as follows. Life span measurements were performed as previously described 23 except for the heat stress experiments where strains were incubated after each dissection at 37°C. Stress resistance assays were performed using mid- log phase cells. Silencing was assayed as previously described 23 .
- Protein expression analysis were conducted as follows. Strains were pretreated under the indicated conditions and grown to mid-log phase. Western blots were performed as described 23 using whole cell extracts (75 ⁇ g). Proteins were detected using anti-GFP antibodies (Santa Cruz) or anti-actin antibodies (Chemicon). Fluorescent microscopy images were captured at the same exposure (1 s) at lOOx magnification with a Hamamatsu OrcalOO CCD camera and processed with Openlab software.
- Nicotinamidase activity assay was conducted as follows. Activity of Pncl in extracts obtained from pretreated mid-log phase cultures was determined as previously described 41 . Briefly, 0.16 mg of protein were incubated with either 0 or 8 mM nicotinamide for 45 min at 30°C in a final volume of 400 ⁇ l consisting of 10 mM Tris pH 7.5, 150 mM NaCl and 1 mM MgCl 2 . Pncl activity was determined by measuring the final concentration of the reaction product, ammonia, using the Sigma ammonia diagnostic kit. Baseline ammonia was accounted for by subtracting a no nicotinamide control.
- Nicotinamidase activity was expressed as nmol ammonia produced/min/mg total protein. Pncl activity was obtained by subtracting the background value for the ? «c7--l strain (0.06 ⁇ 0.004 nmol/min/mg).
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11179088A EP2431480A3 (en) | 2002-08-09 | 2003-08-08 | Methods and compositions for increasing the stress resistance of cells and organisms |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40225402P | 2002-08-09 | 2002-08-09 | |
US402254P | 2002-08-09 | ||
US42861402P | 2002-11-22 | 2002-11-22 | |
US428614P | 2002-11-22 | ||
PCT/US2003/025016 WO2004016726A2 (en) | 2002-08-09 | 2003-08-08 | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1551964A2 true EP1551964A2 (en) | 2005-07-13 |
EP1551964A4 EP1551964A4 (en) | 2010-07-28 |
Family
ID=31720582
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11179088A Withdrawn EP2431480A3 (en) | 2002-08-09 | 2003-08-08 | Methods and compositions for increasing the stress resistance of cells and organisms |
EP03788377A Withdrawn EP1551964A4 (en) | 2002-08-09 | 2003-08-08 | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11179088A Withdrawn EP2431480A3 (en) | 2002-08-09 | 2003-08-08 | Methods and compositions for increasing the stress resistance of cells and organisms |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP2431480A3 (en) |
JP (3) | JP2005535342A (en) |
AU (2) | AU2003264037B2 (en) |
CA (2) | CA2421269A1 (en) |
WO (1) | WO2004016726A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8158856B2 (en) * | 2006-03-21 | 2012-04-17 | Bayer Cropscience Nv | Stress resistant plants |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
US20060025337A1 (en) | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
WO2006072809A2 (en) * | 2003-10-31 | 2006-07-13 | Robarts Research Institute | Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions |
EP1708689A2 (en) | 2003-12-29 | 2006-10-11 | The President and Fellows of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
CA2567848A1 (en) * | 2004-06-04 | 2006-01-05 | Washington University | Methods and compositions for treating neuropathies |
PT1794306E (en) * | 2004-09-24 | 2010-03-22 | Bayer Bioscience Nv | Stress resistant plants |
WO2006081329A2 (en) * | 2005-01-25 | 2006-08-03 | The Johns Hopkins University | Strategies for designing drugs that target the sir2 family of enzymes |
EP1877054A2 (en) | 2005-03-30 | 2008-01-16 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
DE602006008459D1 (en) * | 2005-06-15 | 2009-09-24 | Bayer Bioscience Nv | PLANTS AGAINST HYPOXIC CONDITIONS |
JP5452022B2 (en) | 2006-12-11 | 2014-03-26 | 独立行政法人科学技術振興機構 | Plant growth regulator and use thereof |
US8268748B2 (en) | 2007-11-13 | 2012-09-18 | Japan Science And Technology Agency | Composition for production of plant body having improved sugar content, and use thereof |
JP5570731B2 (en) * | 2008-02-28 | 2014-08-13 | 旭化成ファーマ株式会社 | Method for measuring pyrophosphate |
WO2009108999A1 (en) | 2008-03-03 | 2009-09-11 | Ross Stewart Grant | Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders |
JP2011115098A (en) * | 2009-12-04 | 2011-06-16 | Nippon Menaade Keshohin Kk | Method for evaluating skin for predicting reduction of skin brightness by aging |
US9930887B2 (en) | 2011-12-12 | 2018-04-03 | Okayama Prefecture | Compound for increasing amino acid content in plant, and use thereof |
WO2014059034A2 (en) | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
US20160287621A1 (en) * | 2013-11-06 | 2016-10-06 | President And Fellows Of Harvard College | Biological production of nad precursors and analogs |
JP2017518306A (en) | 2014-06-02 | 2017-07-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Production and use of crystalline β-D-nicotinamide riboside |
EP3152220A1 (en) | 2014-06-06 | 2017-04-12 | Glaxosmithkline Intellectual Property (No. 2) Limited | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof |
WO2020097116A1 (en) * | 2018-11-05 | 2020-05-14 | Rejuvenation Therapeutics | Compositions and methods for culturing yeast cells |
CN111394268B (en) * | 2019-12-20 | 2021-06-18 | 合肥康诺生物制药有限公司 | Genetically engineered bacterium, construction method and application thereof, and NAD (nicotinamide adenine dinucleotide) production+Method (2) |
CN112451673A (en) * | 2020-12-10 | 2021-03-09 | 汤臣倍健股份有限公司 | Application of mitochondrial function intervention material in preparation of health-care product or medicine for improving mitochondrial function and screening method thereof |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
EP0228458B2 (en) | 1985-07-05 | 1997-10-22 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
DE3852823T2 (en) | 1987-09-11 | 1995-05-24 | Whitehead Biomedical Inst | TRANSDUCTION-CHANGED FIBROBLASTS AND THEIR USE. |
DE3851153T2 (en) | 1987-12-11 | 1995-01-05 | Whitehead Biomedical Inst | GENETIC MODIFICATION OF ENDOTHELIAL CELLS. |
EP0732397A3 (en) | 1988-02-05 | 1996-10-23 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
EP0556345B2 (en) | 1990-10-31 | 2005-10-12 | Cell Genesys, Inc. | Retroviral vectors useful for gene therapy |
WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
WO1994006920A1 (en) | 1992-09-22 | 1994-03-31 | Medical Research Council | Recombinant viruses displaying a nonviral polypeptide on their external surface |
WO1994011524A1 (en) | 1992-11-09 | 1994-05-26 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Targetable vector particles |
FR2705686B1 (en) | 1993-05-28 | 1995-08-18 | Transgene Sa | New defective adenoviruses and corresponding complementation lines. |
ATE399873T1 (en) | 1993-07-13 | 2008-07-15 | Centelion | DEFECTIVE ADENOVIRUS VECTORS AND THEIR USE IN GENE THERAPY |
US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
WO1995034671A1 (en) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
US6001557A (en) | 1994-10-28 | 1999-12-14 | The Trustees Of The University Of Pennsylvania | Adenovirus and methods of use thereof |
US5872005A (en) | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
CA2206683A1 (en) | 1994-12-12 | 1996-06-20 | Genetic Therapy, Inc. | Improved adenoviral vectors and producer cells |
EP0811073B1 (en) | 1995-02-24 | 2007-01-24 | The Trustees Of The University Of Pennsylvania | Use of immune modulators for making medicaments ot inhibit immune responses against co-administered recombinant viruses |
US5688676A (en) | 1995-06-07 | 1997-11-18 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
CA2625279A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
GB9816781D0 (en) | 1998-07-31 | 1998-09-30 | Univ London | Herpes virus vectors for dendritic cells |
CN1478149A (en) * | 2000-10-03 | 2004-02-25 | 宝生物工程株式会社 | Method of screening physiologically active substance |
US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
US9515947B1 (en) | 2013-03-15 | 2016-12-06 | EMC IP Holding Company LLC | Method and system for providing a virtual network-aware storage array |
KR20160071054A (en) | 2014-12-11 | 2016-06-21 | 에스케이하이닉스 주식회사 | Semiconductor memory device and operating method thereof |
US9609948B2 (en) | 2015-04-28 | 2017-04-04 | Qianglong Furniture Co., Ltd. | Rotating armrest apparatus |
-
2003
- 2003-03-07 CA CA002421269A patent/CA2421269A1/en not_active Abandoned
- 2003-08-08 AU AU2003264037A patent/AU2003264037B2/en not_active Ceased
- 2003-08-08 EP EP11179088A patent/EP2431480A3/en not_active Withdrawn
- 2003-08-08 CA CA002495185A patent/CA2495185A1/en not_active Abandoned
- 2003-08-08 EP EP03788377A patent/EP1551964A4/en not_active Withdrawn
- 2003-08-08 WO PCT/US2003/025016 patent/WO2004016726A2/en active Search and Examination
- 2003-08-08 JP JP2004529297A patent/JP2005535342A/en active Pending
-
2010
- 2010-07-20 JP JP2010162637A patent/JP2011015682A/en active Pending
- 2010-09-10 AU AU2010219395A patent/AU2010219395B2/en not_active Ceased
-
2015
- 2015-06-10 JP JP2015117465A patent/JP6602561B2/en not_active Expired - Fee Related
Non-Patent Citations (6)
Title |
---|
CROWLEY C L ET AL: "The NAD+ precursors, nicotinic acid and nicotinamide protect cells against apoptosis induced by a multiple stress inducer, deoxycholate" CELL DEATH AND DIFFERENTIATION, vol. 7, no. 3, March 2000 (2000-03), pages 314-326, XP953224 Great Britain ISSN: 1350-9047 DOI: 10.1038/sj.cdd.4400658 * |
DRAGOVIC J ET AL: "Phase I/II study of pentoxifylline and nicotinamide in combination with radiation therapy in locally advanced cancers" INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 24, no. SUPPL. 1, 1992, pages 272-273, XP26844395 & 34TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY, SAN DIEGO, CALIF ISSN: 0360-3016 * |
GOTOH HIROKO: "Inhibitory effects of nicotinamide on the growth of transplanted murine breast cancer and urethane-initiated lung tumorigenesis in mice" VITAMINS, vol. 67, no. 9, 1993, pages 469-479, XP8036628 KYOTO ISSN: 0006-386X * |
KNIP M ET AL: "Safety of high-dose nicotinamide: A review" DIABETOLOGIA, vol. 43, no. 11, November 2000 (2000-11), pages 1337-1345, XP9134696 Germany ISSN: 0012-186X DOI: 10.1007/s001250051536 * |
See also references of WO2004016726A2 * |
SESTILI P ET AL.: "Structural requirements for inhibitors of poly(ADP-ribose) polymerase." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, LNKD- PUBMED:2123880, vol. 116, no. 6, 1990, pages 615-622, XP9134778 GERMANY ISSN: 0171-5216 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8158856B2 (en) * | 2006-03-21 | 2012-04-17 | Bayer Cropscience Nv | Stress resistant plants |
Also Published As
Publication number | Publication date |
---|---|
JP6602561B2 (en) | 2019-11-06 |
WO2004016726A3 (en) | 2005-05-19 |
JP2011015682A (en) | 2011-01-27 |
JP2015198665A (en) | 2015-11-12 |
EP2431480A2 (en) | 2012-03-21 |
AU2010219395A1 (en) | 2010-09-30 |
CA2495185A1 (en) | 2004-02-26 |
AU2003264037A1 (en) | 2004-03-03 |
EP2431480A3 (en) | 2012-09-05 |
WO2004016726A2 (en) | 2004-02-26 |
AU2010219395B2 (en) | 2011-07-14 |
JP2005535342A (en) | 2005-11-24 |
WO2004016726A9 (en) | 2005-08-04 |
EP1551964A4 (en) | 2010-07-28 |
AU2003264037B2 (en) | 2010-06-17 |
CA2421269A1 (en) | 2004-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010219395B2 (en) | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms | |
EP1851240B1 (en) | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms | |
Vlach et al. | Phosphorylation‐dependent degradation of the cyclin‐dependent kinase inhibitor p27Kip1 | |
Moss et al. | Identification of the cAMP-dependent protein kinase and protein kinase C phosphorylation sites within the major intracellular domains of the beta 1, gamma 2S, and gamma 2L subunits of the gamma-aminobutyric acid type A receptor. | |
Spencer et al. | PSTPIP: a tyrosine phosphorylated cleavage furrow–associated protein that is a substrate for a PEST tyrosine phosphatase | |
AU699969B2 (en) | Isolated p27 protein and its encoding nucleic acid molecules | |
Nakae et al. | Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR | |
Chen et al. | Identification of Nck family genes, chromosomal localization, expression, and signaling specificity | |
Nishijima et al. | A dual-specificity phosphatase Cdc25B is an unstable protein and triggers p34cdc2/cyclin B activation in hamster BHK21 cells arrested with hydroxyurea | |
Echtay et al. | Uncoupling proteins: Martin Klingenberg's contributions for 40 years | |
US7572575B2 (en) | SIR2 activity | |
Dierks et al. | Actin cytoskeletal association of cytohesin-1 is regulated by specific phosphorylation of its carboxyl-terminal polybasic domain | |
Day et al. | Zinc-dependent structural stability of human Sonic hedgehog | |
US6635450B1 (en) | Isolated P27 protein, nucleic acid molecules encoding same, methods of identifying agents acting on same, and uses of said agents | |
US6355774B1 (en) | Isolated p27 protein | |
US20020110886A1 (en) | Isolated p27 protein and methods for its production and use | |
Xu | Identification of Wnt/GSK3 Regulated Proteolysis Targets in Addition to [B]-catenin | |
Ibarra-Sánchez | Biochemical and cellular function of t-cell protein tyrosine phosphatase | |
GUILEAULT | B. Sc., McGill University, 1997 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050308 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100628 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/50 20060101ALI20100622BHEP Ipc: C07K 14/47 20060101ALI20100622BHEP Ipc: A61K 38/45 20060101ALI20100622BHEP Ipc: A01N 25/00 20060101ALI20100622BHEP Ipc: C07H 21/04 20060101ALI20100622BHEP Ipc: C12Q 1/58 20060101ALI20100622BHEP Ipc: C12Q 1/00 20060101ALI20100622BHEP Ipc: C12N 1/20 20060101ALI20100622BHEP Ipc: C12N 9/12 20060101ALI20100622BHEP Ipc: G01N 33/573 20060101AFI20100622BHEP |
|
17Q | First examination report despatched |
Effective date: 20110217 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110830 |